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PREFACE 
PREFACE 
 
The aim of the thesis entitled „Structural Magnetic Resonance Imaging in Amyotrophic 
Lateral Sclerosis” is to evaluate the potential of cortical morphometry, diffusion properties, 
and lesion detection as magnetic resonance imaging (MRI) biomarkers for the state and 
progression of Amyotrophic Lateral Sclerosis (ALS). The thesis is composed of three 
chapters: introduction, projects, and concluding remarks. The three subprojects of the 
thesis are listed on page 8 and 9. The references of all three projects are merged in one 
bibliography at the end of the thesis. 
All three projects were submitted to peer-reviewed journals (impact factor > 1.5) and 
entered their review process. One out of the three projects is successfully published. 
Chapter 2 includes the pre-print version of the published project with permission from 
publishers. Yet unpublished projects are represented in their most recently revised 
versions. The manuscripts of all subprojects are consistently formatted according to the 
guidelines of American Psychological Association (APA). Numbers of figures and tables 
are adapted. No other changes have been made to the manuscripts.   
The thesis has been conducted on behalf of a multidisciplinary treatment program and 
within GO-Bio Funding of BMBF. Contributions of co-authors are listed on page 8 and 9. 
The past three years of PhD thesis have yielded two other publications of the team and 
colleagues. These articles are not included in the thesis, as they are not related to ALS 
biomarker research.  
 
Frank, S. M., Wirth, A. M. & Greenlee, M. W. (2016). Visual-Vestibular Processing In 
The Human Sylvian Fissure. J Neurophysiol, 116, 263-271 
 
Wirth, A. M., Frank, S. M, Greenlee, M. W. & Beer, A. L. (2018). White Matter 
Connectivity of the Visual-Vestibular Cortex Examined by Diffusion-weighted 
imaging. Brain Connectivity, 8, 235-244 
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ABSTRACT 
ABSTRACT  
 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease primarily 
affecting the motor system of the central nervous system. The aim of this thesis is to 
evaluate the potential of structural magnetic resonance imaging (MRI) biomarkers of the 
brain grey matter (GM) and white matter (WM) for the state and progression of ALS. The 
thesis has been conducted on behalf of a treatment program on a named patient basis at the 
University Hospital of Regensburg. 31 patients with written informed consent are 
compared to a control sample of 34 age-matched healthy participants. Routine MRI scans 
have been conducted approximately every 3 months and include T1-weighted imaging, 
diffusion weighted imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) 
sequences at 1.5 Tesla. The subprojects of the thesis investigate precentral and postcentral 
cortical thinning (study 1), spread of alterations of fractional anisotropy (FA) across 
different WM types (study 2), and FLAIR lesion detection (study 3) in the same ALS 
cohort. Candidate MRI biomarkers are associated with neurophysiological and clinical 
biomarkers. Statistical analysis includes both cross-sectional and longitudinal analyses. 
Special focus is set on the individual patient. Cortical thinning is more pronounced in the 
precentral cortex than in the postcentral cortex. Combinatory biomarker use reveals evident 
differences in temporal dynamics of cortical thickness, clinical and neurophysiological 
biomarkers over time. Reduction of FA is consistently detected in the corticospinal tract 
(CST) and extra motor WM and most pronounced in the brainstem. Spread of FA 
alterations resembles both dying-forward and dying-back disease propagation and is not 
linked to patients’ clinical or demographic characteristics. WM lesions as detected by 
FLAIR hyperintensity are more frequent in ALS patients than in controls, most 
pronounced in the CST, and associated with an inferior survival. Together, the findings of 
this thesis suggest that MRI biomarkers may contribute to the diagnosis, prognosis and 
understanding of ALS disease and disease courses on an individual scope.  
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CHAPTER 1: INTRODUCTION 
CHAPTER 1: INTRODUCTION  
 
RATIONALE, AIMS AND HYPOTHESES  
 
ALS is a fatal neurodegenerative disease primarily affecting the motor system (Mitchell & 
Borasio, 2007). Research and clinical treatment are challenged by a broad heterogeneity of 
clinical phenotypes (Swinnen & Robberecht, 2014), complex and late diagnosis (Al-
Chalabi et al., 2016), and lack of understanding of pathogenesis (Morgan & Orrell, 2016). 
To date, only two medications (Riluzole, Edaravone) are FDA approved (Mitsumoto, 
Brooks, & Silani, 2014). In Europe, only Riluzole is approved and known for its marginal 
effect on survival (Miller, Mitchell, & Moore, 2012). Multidisciplinary research has 
revealed differentiated insights into possible pathogenic processes (Morgan & Orrell, 
2016). Still, the vision of the Motor Neuron Disease Association (MNDA) to finally cure 
ALS (Mitchell & Borasio, 2007) is distant (Schultz, 2018). Biomarkers are biological 
correlates (Benatar et al., 2016) and may pave the way to ALS treatment by their 
contributions to timely diagnosis, estimation of individual prognosis and early assessment 
of treatment effects (Al-Chalabi et al., 2016). Moreover, different biomarkers may be 
combined in clinical trial designs to reveal benefits of medication for subtypes of ALS 
(Benatar et al., 2016). Aside from routine clinical and neurophysiological biomarkers, 
multimodal neuroimaging provides potential biomarkers for the classification of ALS 
subtypes and for understanding the pathogenesis of ALS (Turner & Verstraete, 2015).  
The aim of this thesis is to evaluate the potential of different MRI techniques as diagnostic 
and prognostic biomarkers for ALS. The focus is set on the combination with other 
biomarkers and the perspective on the individual patient in the state and course of disease.  
Study 1 investigates cortical thinning of the precentral and postcentral cortex in ALS. 
Brain MRI is combined with neurophysiological and clinical biomarkers. The 
neurophysiological biomarker is assessed at the hand muscles of patients. The cross-
sectional data analysis explores individual states of cortical thinning in addition to group 
averages. Longitudinal analysis investigates differences in temporal dynamics of 
multimodal biomarker use.  
Study 2 targets the controversy of the dying-forward and dying-back hypotheses, which 
have gradually lost attention in the past years. Most studies focus on motor-associated WM 
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only. Here, the approach is to reveal sequential alterations in diffusion properties of 
different hierarchical types of WM: brainstem WM, projection fibers, association fibers, 
commissural fibers. Alterations in diffusion properties are associated with clinical and 
demographic data of patients.  
Study 3 aims at the evaluation of conventional FLAIR imaging for the diagnosis and 
prognosis of ALS. FLAIR imaging is underrepresented in ALS research due to 
controversial specificity for ALS and lack of objective quantification studies. An 
automated segmentation toolbox established in multiple sclerosis research enables the fast 
and objective quantification of FLAIR lesions and may be a promising tool for FLAIR data 
analysis in ALS.  
The following section will provide background information on ALS, biomarkers, and MRI. 
This information will underline the motivation behind the three studies involved in this 
thesis.  
 
BACKGROUND                                                                                                                                               
 
MOTOR NEURONS IN HEALTH AND DISEASE 
 
Motor neurons (MN) are neuronal cells of the central nervous system (CNS) and essential 
for the transduction of signals from the brain and spinal cord to the muscles enabling 
movement of the body (Stifani, 2014). For this purpose, MNs need to be involved in both 
neuronal circuits and innervation of muscles. MNs are characterized by long axons, 
complex signal processing and connectivity to both CNS and periphery (Parson, 2014). 
MNs may be differentiated into so-called upper motor neurons (UMN) and lower motor 
neurons (LMN) (Stifani, 2014). UMNs are located in the motor and premotor cortex and 
connect to LMN arranged in the brainstem and spinal cord of the motor system. LMNs 
receive signals from UMNs, sensory neurons and interneurons, and transduce the signal to 
the muscle targets outside of the CNS. Facing the central role and great size/length of 
MNs, it is no surprise that MNs require distinct supply of energy and may be especially 
vulnerable to damage and disease (Parson, 2014). Damage to UMNs leads to muscle 
weakness (paresis), increased muscle tone (spasticity) and brisk reflexes (Ivanhoe & 
Reistetter, 2004). In contrast, lesions of LMNs may lead to paresis and muscle atrophy as 
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no CNS signal can be transferred to muscles (Stifani, 2014). Fineberg et al. (2013) 
revealed that neuromuscular disorders represent some of the most cost-intense diseases in 
the United Kingdom. Still, research claims a better understanding of pathogenic processes 
behind motor neuron diseases (MND) (Parson, 2014). ALS as the most common MND is 
the focus of this thesis and is described in the following section.  
 
AMYOTROPHIC LATERAL SCLEROSIS  
 
“Let us keep looking, in spite of everything. Let us keep searching. It is indeed the best 
method of finding, and perhaps thanks to our efforts, the verdict we will give such a patient 
tomorrow will not be the same we must give this man today.”  
                                                                                                    Charcot (1889) 
From Charcot to ice buckets 
ALS has first been described and termed by Charcot in 1869 (Charcot, 1869). More than 
100 years later, this disease has increasingly attracted scientific and clinical interest 
(Kiernan et al., 2011). The first clinical trials started in the 1980s and the first standard 
diagnostic criteria were established and revised in the 1990s (Mitsumoto et al., 2014). 
Since then, multidisciplinary research has revealed various phenotypes, pathogenic 
processes, and genetic variants of ALS and has paved the way for therapeutic interventions 
(Rosenfeld & Strong, 2015). The social media presence of the Ice Bucket Challenge in 
2014 has not only increased worldwide attention on this disease, but has also raised more 
than 140 million dollars of donations for research funding (Hrastel & Robertson, 2016).  
 
What is Amyotrophic lateral sclerosis? 
ALS is a rapidly progressive and incurable neurodegenerative disease primarily affecting 
MNs of the brain and the spinal cord (Calvo et al., 2014). Degeneration of both LMNs and 
UMNs leads to paresis, muscle wasting, fasciculation, cramps, paralysis, difficulty 
speaking, swallowing, and shortness of breath (Bozzoni, 2016). The onset of motor 
symptoms is related to voluntary limb muscles (limb-onset) or the function of speech and 
swallowing (bulbar-onset), rarely respiratory muscles. Involvement of non-motor areas of 
the brain may also lead to deficits in behavior and cognition (Goldstein & Abrahams, 
2013).  
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ALS is a rare disease with a prevalence of 7-9/100 000 persons and an incidence rate of 
2.6/100 000 persons per year based on European registers (Hardiman et al., 2017). 
Prevalence of ALS evidently varies across different cultures and geographical origins (Van 
Es et al., 2017). Comparisons of epidemiological registers of ALS may be challenged by 
heterogeneous disease onset and differences in diagnostic criteria (Hardiman et al., 2017). 
Incidence of ALS has been observed to gradually increase. This phenomenon may be 
linked to enhanced attention to this disease, improved diagnostic criteria and recognition of 
various phenotypes of ALS. ALS is usually diagnosed at a mean age of 65 years (Turner, 
Barnwell, Al-Chalabi, & Eisen, 2012). However, ALS may also occur at young age 
(young-onset ALS). Risk of ALS is considered to be higher for males than females (1.6:1) 
(Mitchell & Borasio, 2007). The devastating character of ALS is underlined by grave 
survival prognosis (Paulukonis et al., 2015) and high mortality rates (1.70 per 100 000 
population, 2014, USA) (Larson, Kaye, Mehta, & Horton, 2018). 
Standardized ALS diagnosis has been enabled by El Escorial Diagnostic Criteria since 
1994 (Brooks, 1994). Since then, El Escorial criteria have been revised and adapted to 
increasing knowledge about ALS and the advancement of clinical methods (Al-Chalabi et 
al., 2016; Ludolph et al., 2015). Diagnostic criteria are based on the presence and extent of 
so called UMN and LMN signs. LMN signs are characterized by muscle atrophy, 
weakness, fasciculation and weak or absent reflexes (Swinnen & Robberecht, 2014). UMN 
signs are considered positive Babinski sign, positive Hoffman sign, spasticity and brisk 
reflexes. Special respect is given to the localization (bulbar, spinal regions) and extent 
(number of regions) of UMN and LMN signs (Al-Chalabi et al., 2016). The most recently 
revised criteria (Costa, Swash, & Carvalho, 2012; Table 1.1) define definite, probable or 
possible ALS (Table 1.1). Aside from the presence of both UMN and LMN signs and a 
progressive character of disease, ALS diagnosis bases upon the exclusion of mimic 
diseases, especially treatable diseases (Al-Chalabi et al., 2016). Differential diagnosis 
requires the exclusion of other treatable diseases by detailed anamnesis, diagnostic 
findings, and monitoring of clinical progress (Swinnen & Robberecht, 2014). Mimic 
diseases may be differentiated from ALS by neurophysiological, neuroimaging and 
laboratory findings (Bicchi, Emiliani, Vescovi, & Martino, 2015). The complex process of 
ALS diagnosis usually lasts one year in average and results in a fatal delay of intervention 
(Kiernan et al., 2011). The notification of an ALS diagnosis exposes patients and 
caregivers to an enormous psychological burden and requires adequate and sensible 
communication (Pizzimenti, Gori, Onesti, John, & Inghilleri, 2015). 
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Table 1.1 
Most recent revised form of El Escorial criteria for ALS diagnosis (Costa et al. 2012).  
 Clinical or electrophysiological evidence of UMN and LMN signs  
Definite ALS … in the bulbar region and at least two spinal regions, or UMN and 
LMN signs in three spinal regions 
Probable ALS … in at least two regions, with some UMN signs rostral to LMN signs 
Possible ALS  … in only one region, or UMN signs alone in two or more regions, or 
LMN signs rostral to UMN signs 
 
 
Figure 1.1. Variability of phenotypes of ALS. Figure was adapted from Swinnen & 
Robberecht (2014). ALS phenotypes include spinal-onset (a), bulbar-onset (b), progressive 
muscular atrophy (c), primary lateral sclerosis (d), pseudopolyneuritic ALS (e), hemiplegic 
ALS (f), flail arm (g) and flail leg syndrome (h).  
 
One factor challenging ALS diagnosis is the heterogeneity of ALS phenotypes (Swinnen & 
Robberecht, 2014) (Figure 1.1). ALS phenotypes substantially vary in extent of MN 
involvement (UMN, LMN), onset site (bulbar, spinal), locality of symptoms (distal, 
proximal muscles) and progression. ALS may be differentiated in spinal-onset (Figure 
1.1a) and bulbar-onset (Figure 1.1b). Spinal onset is marked by both UMN and LMN signs 
primarily starting in the limbs of the body. Bulbar onset is less frequent (20% of patients) 
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and is characterized by muscular weakness of respiratory muscles, deficits in speech 
(dysarthria) and swallowing (dysphagia). Progressive muscular atrophy (Figure 1.1c) and 
primary lateral sclerosis (Figure 1.1d) belong to the spectrum of ALS-MND where ALS 
includes the deterioration of both LMN and UMN at different degrees. ALS symptoms 
may also be specific to distal limbs (Figure 1.1e), to one body side (Figure 1.1f), to upper 
limbs (Figure 1.1g), or to lower limbs (Figure 1.1h). Aside from motor symptoms, ALS 
may include cognitive deficits in speech and executive functions (Beeldman et al., 2016). 
ALS may even overlap with behavioral variant frontotemporal dementia (Bozzoni, 2016). 
Moreover, ALS patients may exhibit pathological laughing and crying (pseudobulbar 
signs) (Mitchell & Borasio, 2007), affective disturbances (depression, anxiety) (Carvalho 
et al., 2016), sleep disorders (Mitchell & Borasio, 2007) or pain (Chiò & Lauria, 2017). 
The ALS patient cohort of this thesis involves spinal-onset and bulbar-onset ALS. The 
majority of ALS patients are diagnosed spinal-onset ALS. Study 1 and 2 include only 
spinal-onset classical ALS patients exhibiting similar UMN and LMN involvement. Study 
3 involves spinal-onset as well as bulbar-onset patients.  
Despite the discovery of various pathogenic mechanisms in ALS, the etiology explaining 
all of these processes remains unclear (Van Es et al., 2017). Multifactorial pathogenesis of 
ALS may already start early in life and long before ALS is diagnosed in late adulthood 
(Eisen, Kiernan, Mitsumoto, & Swash, 2014). ALS is associated with a variety of genetic 
mutations affecting processing of deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA) (Morgan & Orrell, 2016). Probably the most important genetic targets in ALS may 
be chromosome 9 open reading frame 72 (C9orf72), superoxide dismutase 1 (SOD1), TAR 
DNA-binding protein 43 (TARDBP) and RNA-binding protein FUS (fused in sarcoma). 
SOD1 mutations are associated with functional and structural cell damage induced by 
active oxygen species (oxidative stress) (Adly, 2010; Morgan & Orrell, 2016). Mutations 
in C9orf72, TARDBP and FUS may lead to disturbed transcription of DNA to RNA and 
deficient translation of RNA to proteins (Morgan & Orrell, 2016). Malformations and 
dysfunctions of proteins may then result in cytotoxic protein aggregations. Accumulations 
of misfolded proteins are observed to spread across the whole brain in the course of disease 
(Brettschneider et al., 2013). Spread of protein aggregations in the CNS is a feature of ALS 
common with other neurodegenerative diseases like Alzheimer’s disease and Parkinson’s 
disease (Lee & Kim, 2015). This observation leads to the controversial theory of ALS 
being a prion-like disease (Ludolph & Brettschneider, 2015). The involvement of both 
UMN and LMN in ALS is also the basis for another controversy: Does ALS begin in UMN 
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or LMN? Two attempts trying to answer this question are the famous dying-forward and 
dying-back hypotheses (Kiernan et al., 2011). Dying-forward hypothesis postulates the 
origin of ALS in the motor cortex of the brain. The so-called anterograde degenerative 
process may be mediated by glutamate excitotoxicity. Dying-back hypothesis proposes the 
start of ALS in the LMNs or at the neuromuscular junction of the muscles. Based on this 
theory, lack of neurotrophic hormones may lead to a retrograde degenerative mechanism. 
Aside from disturbances in DNA/RNA processing and protein aggregations, various other 
pathogenic mechanisms have been associated with MN degeneration in ALS: 
mitochondrial dysfunction, disturbances in glial cells and cytoskeleton, defects in vesicle 
transport, excitotoxicity or immune dysfunction (Van Damme, Robberecht, & van den 
Bosch, 2017).  
 
Although a variety of genetic mutations have been revealed, hereditary (familial) ALS 
represents only 5-10% of ALS cases (Kiernan et al., 2011). The majority of ALS patients 
exhibit no familiar background of ALS, and are therefore considered sporadic.  
Only three patients of the ALS patient cohort involved in this thesis are diagnosed with 
familial ALS. Genetic screening revealed the prominent SOD1, resp. C9Orf mutations.  
The interaction of genetic predisposition and environmental risk factors may also play an 
essential role in ALS (Morgan & Orrell, 2016). Risk factors of ALS have been discussed to 
involve body mass index, physical activity, traumatic events, smoking, ingestion of heavy 
metals, pesticides, electric shocks, and cyanotoxins (Ingre, Roos, Piehl, Kamel, & Fang, 
2015; Morgan & Orrell, 2016). However, the interplay of trigger factors and genetic 
predisposition and thus the validity of risk factors remain unclear (Ingre et al., 2015).  
Knowing possible pathogenic pathways in ALS has given rise to the development of 
disease-modifying drugs with various modes of actions (Dorst, Ludolph, & Huebers, 
2018). However, as of date, more than 30 drugs tested in clinical trials have failed to 
prolong survival (Garbuzova-Davis, Thomson, Kurien, Shytle, & Sanberg, 2016). Survival 
in ALS is 3-5 years from symptom onset (Calvo et al., 2014). In bulbar-onset ALS, 
patients even suffer from inferior survival of only 2 years (Swinnen & Robberecht, 2014). 
Study 1 focuses on the interplay of UMN and LMN by the combinatory use of potential 
UMN biomarker cortical thickness and a potential LMN neurophysiological biomarker. 
Study 2 investigates the Dying-forward and Dying-back hypotheses by examination of 
diffusion properties of different hierarchical WM types.  
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The only approved medication worldwide since 1995 is Riluzole, which prolongs survival 
to an extent of only 3-6 months (Dorst et al., 2018). In 2017, Edaravone has been approved 
for ALS treatment only in Japan and in the United States of America (Bhandari & Kuhad, 
2018). Edaravone targets oxidative stress and slows down disease progression of a 
homogenous subgroup of early ALS patients – there is no survival benefit so far. The 
failure of clinical trials may be explained by inadequate animal models, failed crossing of 
blood-brain-barrier, and challenges of clinical study design (e.g. short trials, low sample 
sizes) (Garbuzova-Davis et al., 2016). Moreover, heterogeneous phenotypes of ALS, fast 
progression and late diagnosis may reduce the chance of finding significant benefits of 
drug treatment in ALS clinical trials (Al-Chalabi et al., 2016; Swinnen & Robberecht, 
2014). Aside from disease-modifying intervention, ALS may only be treated 
symptomatically (Dorst et al., 2018). Nutritional management (e.g. high-caloric diet) aims 
at the maintenance of body weight. Ventilation devices are relevant for the treatment of 
respiratory insufficiency. Physiotherapy may help to reduce spasticity or muscle cramps. 
Additional medication (e.g. antidepressants, opioids, botulinum toxins) may support the 
symptomatic treatment of depression, emotional lability, insomnia, or excessive salivation 
(sialorrhoe). Facing the inexorable progression of disease, many ALS patients voluntarily 
agree to treatment with promising but not yet approved medication (off-label use) (Kiernan 
et al., 2011). The thesis has been conducted on the behalf of a treatment program, which is 
introduced in the following section.   
 
Filgrastim treatment on a named ALS patient basis  
Granulocyte-colony stimulating factor (G-CSF) is considered a neurotrophic factor for 
MNs and a potential target for ALS treatment (Pitzer et al., 2008). Receptors of G-CSF are 
expressed in various brain regions and G-CSF properties allow for passage of the blood 
brain barrier (Schneider et al., 2005). Potential effects of G-CSF on neurogenesis and 
plasticity of vasculature have lead to increasing relevance of G-CSF for therapy of stroke 
(Schäbitz & Schneider, 2007; Wallner et al., 2015), psychiatric and neurodegenerative 
diseases (Schneider et al., 2005). In SOD1 mouse model of ALS, G-CSF treatment 
counteracts muscle atrophy, increases survival of MNs, improves motor performance and 
prolongs survival of mutant mice (Pitzer et al., 2008). In humans, G-CSF is well tolerated 
and shows a trend of slowing ALS progression (Nefussy et al., 2010). The lack of 
significant beneficial documented effects of G-CSF so far is believed to result from small 
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sample sizes, low dosages, short treatment and lack of suitable biomarkers (Duning et al., 
2011; Nefussy et al., 2010). Dense dose application and longitudinal G-CSF–treatment up 
to 3 years are well tolerated and replicate effects on bone marrow function (Grassinger et 
al., 2014). The treatment program of G-CSF (Filgrastim) with written informed consent 
involves 36 patients in a treatment observation period since January 2010. All patients 
have been treated with standard Riluzole and additional G-CSF on a named patient basis. 
Doses and application modes of G-CSF have been individually adapted. Treatment 
duration is up to eight years. Safety and monitoring have been ensured by monthly clinical 
examinations and acquisition of biomarkers in regular intervals. Neuroimaging has been 
conducted approximately every three months. Neuroimaging data has been acquired in 31 
out of 36 patients.  
This treatment program includes no control group without G-CSF treatment, as it is not a 
clinical trial. As the thesis has been conducted on the behalf of the Department of 
Experimental Psychology, the focus is set on neuroimaging biomarkers rather than 
medicinal effects of G-CSF.   
 
BIOMARKERS  
 
The demand of valid biomarkers is urgent for the classification of ALS and the evaluation 
of therapeutic effects (Cheah, Vucic, Krishnan, Boland, & Kiernan, 2011). A biomarker is 
roughly termed a measurable correlate for biological processes (Benatar et al., 2016). 
However, biomarkers may have diagnostic, prognostic, predictive and pharmacodynamical 
functions. Diagnostic biomarkers are essential for the decision, whether patients should be 
classified as having a disease or not. Prognostic biomarkers enable the estimation of risk or 
progression of disease. Predictive biomarkers help to evaluate the potential outcome of 
therapeutic interventions. Pharmacodynamical biomarkers enable the characterization of 
the biological mode of action of a drug. As of date, multiple candidate biomarkers for ALS 
have been discovered for different domains: Tissues and fluids, electrophysiological 
correlates, neuroimaging markers and clinical indicators (Turner et al., 2013, Table 1.2). 
Saliva, urine, blood and CSF are easily accessible biomarker sources for the analysis of 
proteins involved in molecular pathological mechanisms like neuroinflammation (Turner et 
al., 2013; Vu & Bowser, 2017). Tissue analysis of muscles may help to investigate 
processes of atrophy and denervation (Sorarù et al., 2008). The analysis of post-mortem 
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tissue is highly relevant, but hindered by lack of disposability or limited conservation of 
tissue (Corcia et al., 2008; Turner et al., 2013). Neurophysiological biomarkers may 
include LMN-specific motor number estimation (MUNE), motor unit number index 
(MUNIX), and UMN-specific transcranial magnetic stimulation (TMS) (Vucic, Ziemann, 
Eisen, Hallett, & Kiernan, 2012). These biomarkers enable the quantification of functional 
integrity of LMN and UMN units. Progression of ALS disease is routinely monitored by 
neurological examination and clinical scores (Rutkove, 2015). The most frequently used 
clinical score is the ALS-specific functional rating scale revised (ALSFRS-R). The 
ALSFRS-R includes 12 items concerning functions of speech, salivation, swallowing, 
handwriting, handling utensils, self-care, turning, walking, climbing, shortness of breath 
and respiratory insufficiency (Cedarbaum et al., 1999, Appendix 1). Medical doctors rate 
one score per item from 4 (normal) to 0 (inability) resulting in 48 score points in total. The 
ALSFRS-R is fast and easy to assess and is considered a reliable correlate to survival 
(Gordon, Miller, & Moore, 2004). Non-invasive neuroimaging of the brain and spinal cord 
has given rise to a variety of promising biomarkers relevant to diagnosis and prognosis of 
ALS (Agosta, Spinelli, & Filippi, 2018).  
 
Table 1.2 
Candidate biomarkers for ALS (Turner et al., 2013). MUNE: motor unit number 
estimation, MUNIX: motor unit number index, TMS: transcranial magnetic stimulation, 
ALSFRS-R: ALS-specific functional rating scale revised.  
Method  Focus on …  Candidate biomarkers 
Body-Fluids  CSF, saliva, blood, urine E.g. inflammatory biomarkers 
Tissues Muscle, skin, post-mortem tissue Cell-type analysis 
Neurophysiology Lower motor neuron                                         
Upper motor neuron  
MUNE, MUNIX                    
TMS 
Clinical measures  Disease progression ALSFRS-R 
Neuroimaging  Brain, spinal cord  Various modalities (see below) 
 
Combinatory biomarker use of neuroimaging biomarkers and other biomarker modalities 
may pave the way to find a signature for ALS (Chen & Shang, 2015). The thesis focuses 
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on structural MRI biomarkers of the brain and combines these biomarkers with 
neurophysiological correlates and routine clinical biomarkers. 
In the last twenty years, neuroimaging findings have enormously contributed to the 
understanding of changes in structure and function of the brain in ALS (Chiò et al., 2014). 
The following section will enlarge upon the MRI technique and its relevance as a 
biomarker source for ALS.  
 
MAGNETIC RESONANCE IMAGING   
 
MRI is a non-invasive medical imaging technique enabling the investigation of structure 
and function of the human body (Vijayalaxmi, Fatahi, & Speck, 2015). MRI is based on 
the molecular spin of protons in the presence of an external magnetic field (McMahon, 
Cowin, & Galloway, 2011). The most frequently studied targets of clinical MRI are 
hydrogen nuclei as the human body is composed of high amounts of water. In the absence 
of an external magnetic field, the spin of hydrogen protons is random and driven by 
thermal energy. Based on the positive charge of protons, spin motion generates electrical 
current. The presence of an external magnetic field induces the protons to align their spin 
to the magnetic field in either parallel or antiparallel manner (precession, longitudinal 
magnetization). Parallel state means in the same direction as the magnetic field. The 
parallel state is the preferred alignment as it provides a low energetic status. In the 
antiparallel state, spins of protons are opposite to the external magnetic field. The relation 
of number of spins in parallel to that of antiparallel state is called net magnetization. The 
application of a temporary radiofrequency (RF) pulse of 90° flip angle perpendicular to the 
magnetic field leads to a shift of molecular spin of protons from longitudinal to transverse 
plane and in the same phase. Protons are now in a high energetic status. Protons emit a 
signal to return to low energetic status in the horizontal plane. This signal is detected as 
voltage by a receiver coil. The return of spins to the longitudinal plane is called relaxation 
(Grover et al., 2015). Relaxation may primarily be described by either longitudinal (T1) or 
transverse (T2) relaxation times (McMahon et al., 2011). Longitudinal relaxation (spin-
Study 1 combines MRI cortical thickness with neurophysiological MUNIX and clinical 
data. Study 2 and study 3 use a biomarker combination of MRI with clinical scores, and 
survival.  
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lattice) refers to the restoration of longitudinal magnetization. Transverse relaxation 
describes the loss of transverse magnetization (spin-spin), which is accelerated by spin-
spin interactions or inhomogeneity of the magnetic field. The time needed for T1 or T2 
relaxation strongly depends on the biological characteristics of tissue. T2 relaxation time is 
usually much shorter than T1. Therefore, the application of a 180° spin echo pulse is used 
to restore in-phase spins of protons and delay T2. This procedure prohibits the loss of MRI 
signal. MRI images also include spatial information aside from chemical characteristics of 
tissue (Grover et al., 2015). For this purpose, MRI scanners obtain three sets of gradient 
coils on X, Y and Z axis, which enable the localization of the MR signal.  Grey values of 
voxels (volumetric pixels) of MRI images may be based on T1 and T2 relaxation times, 
diffusion, perfusion and oxygen levels among others (Plewes & Kucharczyk, 2012). 
The thesis focuses on MRI imaging of the brain and different MRI modalities. Study 1 
involves T1-weighted imaging. Study 2 focuses on DWI. Study 3 investigates FLAIR 
imaging.  
T1-weighted imaging is based on relaxation times of spins dependent on characteristics of 
tissue (Grover et al., 2015). The dense structure of bone exhibits short T1 and is visualized 
in bright stain. Fluids like cerebrospinal fluid (CSF) show long T1 resulting in dark stain 
on T1-weighted images. T1 contrast enables the evaluation of disease-associated 
alterations (Maniam & Szklaruk, 2010) as well as the investigation of morphometry 
(volume, area, cortical thickness) of regions of interest (ROI). DWI aims at the 
quantification of movement of water molecules (Grover et al., 2015). Similar to classic 
MRI theory, a RF impulse induces the precession of protons from longitudinal to 
transverse magnetization in-phase. The precession of the dephasing gradient is followed by 
a rephasing gradient in opposite tune. The purpose of the rephasing gradient is to return 
effects of the dephasing gradient. In case of static water molecules, rephasing procedure is 
expected to be complete. If water molecules move between the set of dephasing and 
rephasing gradients, rephasing effects will be incomplete resulting in a reduced MRI 
signal. Based on Brown’s law, water molecules move randomly in all directions 
(isotropic), if the surrounding environment is free of obstacles. Biological structures 
restrict the movement of water molecules. In this case, diffusion is described anisotropic, 
as it is rather directed than free and random. Diffusion of water molecules can be described 
by a 3D ellipsoid called a diffusion tensor. The tensor estimates diffusion by three 
eigenvalues and three eigenvectors. Eigenvalues describe height of diffusion, while 
eigenvectors account for directions of diffusion. In Diffusion tensor imaging (DTI), every 
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voxel of the brain is given a tensor. The resulting map of diffusion also enables the 
reconstruction of WM tracts by following streamlines of diffusion properties. Fractional 
anisotropy (FA) is a frequently used DWI variable of interest describing directivity of 
diffusion. In ALS research, reduced FA is associated with loss of WM tract integrity 
(Menke et al., 2012). In FLAIR imaging, the excitatory RF impulse is preceded by a 180° 
pulse (Bitar et al., 2006). The time window between those two pulses is crucial and called 
inversion recovery time. By the use of specific inversion recovery times, signal of certain 
fluids (e.g. CSF) can be elucidated. This method enables the detailed investigation of 
anatomical details at the borders of the CSF and in the brainstem (Hajnal et al., 1992). In 
neurodegenerative diseases like multiple sclerosis (MS), local hyperintensity signal in 
FLAIR images may be interpreted as WM lesions (Gawne-Cain, Silver, Moseley, & 
Miller, 1997). 
Neuroimaging has provided new insights into the pathogenesis of ALS and has raised 
many potential biomarkers for either presymptomatic or manifested ALS (Turner & 
Verstraete, 2015). The most frequently used MRI techniques in ALS are T1, DWI, FLAIR, 
functional MRI (fMRI) and magnetic resonance spectroscopy (MRS) (Grolez et al., 2016; 
see Table 1.3). Alterations of structure and function of corticospinal tract (CST), motor 
cortex and spinal cord are most consistently reported in ALS (Grolez et al., 2016). 
However, MRI alterations also involve non-motor areas. GM morphometric studies based 
on T1-weighted imaging reveal regional atrophy of the precentral cortex (Chiò et al., 
2014). However, alterations in volume (Grosskreutz et al., 2006) or cortical thickness 
(Agosta et al., 2012) are not consistently reported in all studies. WM degeneration as 
detected by DWI is considered to be a rather consistent marker for ALS (Chiò et al., 2014). 
Studies have revealed reduced FA (Kassubek et al., 2014) and enhanced mean diffusivity 
(Ellis et al., 1999) along the CST and in extra-motor WM areas (Grolez et al., 2016). 
FLAIR imaging as a conventional MRI technique is primarily assessed to exclude ALS 
mimics like MS (Chiò et al., 2014). Despite detection of hyperintensity in CST and corpus 
callosum (Fabes et al., 2017) the specificity and sensitivity of FLAIR imaging for ALS is 
still a matter of debate (Chiò et al., 2014). FMRI has been used to detect alterations in the 
activity of the motor cortex (Mohammadi et al., 2011) or in functional connectivity of the 
sensorimotor network and frontoparietal network (Agosta et al., 2011, 2013). MRS has 
revealed deviations in metabolic concentrations, especially of N-acetyl aspartate and 
choline in the motor cortex (Lombardo et al., 2009). Despite biomarker potential of fMRI 
and MRS, studies using these techniques are still sparse.  
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Table 1.3 
Most frequently used MRI techniques, variables of interest, and exemplary findings in ALS 
research (see review Grolez et al., 2016). DWI: Diffusion weighted imaging, FLAIR: fluid-
attenuated inversion recovery, fMRI: functional magnetic resonance imaging, MRS: 
magnetic resonance spectroscopy, FA: fractional anisotropy, MD: Mean diffusivity, CST: 
corticospinal tract.  
MRI technique Variables of interest Findings  
T1 Volume 
 
Cortical thickness 
Reduced precentral volume (Grosskreutz et al., 
2006) 
Reduced precentral cortical thickness (Agosta 
et al., 2012) 
DWI FA 
 
MD  
Reduced FA along the CST (Kassubek et al., 
2014) 
Enhanced MD along the CST (Ellis et al., 
1999) 
FLAIR Hyperintensity signal Hyperintensity of the CST and the corpus 
callosum (Fabes et al., 2017) 
fMRI Motor task fMRI 
 
Functional and 
structural connectivity 
Elevated activity in the motor cortex 
(Mohammadi et al., 2011) 
Alterations in the sensorimotor network and 
frontoparietal network (Agosta et al., 2011, 
2013)  
MRS Metabolic 
concentration 
Altered peaks of N-Acetylaspartate and choline 
in the motor cortex (Lombardo et al., 2009) 
 
The current thesis focuses on GM morphometry, WM diffusion properties and FLAIR 
lesion detection as potential MRI biomarkers for ALS. Moreover, these MRI biomarkers 
are combined with clinical and neurophysiological biomarkers. Study 1 examines GM 
morphometry by combinatory biomarker use of precentral and postcentral cortical 
thickness with neurophysiological MUNIX and clinical scores. Study 2 investigates WM 
diffusion properties by FA of different WM types associated with clinical data. Study 3 
evaluates a newly established toolbox for the detection and quantification of FLAIR 
alterations in ALS. Preparatory work and the background, methods, and findings of the 
three subprojects are described in the following chapter.  
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CHAPTER 2: PROJECTS  
 
PREPARATORY WORK  
 
INTRODUCTION TO NEUROPHYSIOLOGICAL MUNIX DATA 
The thesis involves MRI biomarkers as well as clinical and neurophysiological biomarkers. 
Therefore, it is necessary to become acquainted with the analysis and interpretation of 
MUNIX data. MUNIX has primarily been assessed in the musculus abductor digiti minimi 
(ADM) of the hand. The ADM is a muscle innervated by the ulnar nerve and in charge of 
movement of the little finger (Muscolino, 2014). Preparatory analysis includes 17 ALS 
patients with MUNIX assessment in the left and right ADM. MUNIX scores averaged 
across left and right hands significantly correlate with corresponding ALSFRS-R sum 
scores (r = .569, p = .017) (Figure 2.1.1A). ALS patients exhibit variable baseline levels 
and different progression of MUNIX over time (Figure 2.1.1B). The heterogeneity of 
baseline levels and progression of MUNIX may be linked to different onsets of disease 
(arm, leg) or different involvement of UMN and LMN. These findings are relevant for 
study 1 combining MRI biomarkers with neurophysiological MUNIX and clinical 
ALSFRS-R.  
 
 
Figure 2.1.1. Preparatory study on MUNIX scores in 17 ALS patients. A) Correlation of 
MUNIX scores with ALSFRS-R scores at baseline. B) Variability of baseline level of 
MUNIX and progress of MUNIX decline over time in 17 individual patients. Illustration of 
the abductor digiti minimi (ADM) muscle of the right hand (adapted from Muscolino, 
2014). MUNIX scores are averaged across left and right ADM.  
 
 
 
28 
CHAPTER 2: PROJECTS 
PILOT TRIAL ON EDINBURGH COGNITIVE AND BEHAVIORAL ALS SCREEN  
ALS patients may exhibit both motor deficits and cognitive impairment (Beeldman et al., 
2016). Cognitive decline may involve speech, executive functions as well as social 
cognition. Frontal Assessment Battery (FAB; Dubois, Slachevsky, Litvan, & Pillon, 2000), 
Montreal Cognitive Assessment (MoCA, Nasreddine et al., 2005) or Mini Mental State 
Examination (MMSE; Tombaugh, McDowell, Kristjansson, & Hubley, 1996) are 
frequently used cognitive screening tools in clinical routine (Lulé et al., 2015).  General 
cognitive decline (MMSE) and frontal cognitive impairment (FAB, MoCA) are 
predominantly detected in ALS patients with the behavioral variant of frontotemporal 
dementia (ALS-FTD) compared to healthy controls (Ohta et al., 2017). However, 
neuropsychological tools like MMSE, FAB, and MoCA may be biased by impaired motor 
performance of ALS patients (Heimrath et al., 2014; Lulé et al., 2015). The Edinburgh 
Cognitive and Behavioral ALS screen (ECAS) is a newly established cognitive screening 
tool, which enables a fast and reliable cognitive screening of ALS patients without motor 
biases (Lulé et al., 2015). It may be performed in either written or oral form. The ECAS is 
composed of a cognitive screen and a behavioral screen. The behavioral screen assesses 
behavioral disinhibition, apathy, empathy, behavioral abnormalities (perseverations, 
stereotypes, compulsive or ritualistic behaviour), nutrition, and includes a psychosis scale. 
The pilot trials focus on only the cognitive screen, as inclusion of the behavioral screen 
would have required more time and the presence of a caregiver (Lulé et al., 2015). The 
ECAS cognitive screen (Appendix 2) includes a so-called ALS-specific and ALS-
nonspecific cognitive domain. ALS-specific cognitive deficits include language and 
executive functions. In contrast, memory or visuospatial abilities are considered to be 
preserved in ALS and account for ALS-nonspecific cognitive abilities. Two patients of the 
treatment program have been enrolled in a pilot estimation on ECAS use. These exams 
have been conducted to evaluate feasibility of this screening tool for prospective use. Both 
patients involved in this examination are male, limb-onset, leg-onset, and exhibit 
comparable education and professional background. Table 2.1.1 lists the results of the two 
pilot exams. ALSFRS-R sum scores at ECAS acquisition day were 29 score points for 
patient 1 and 34 score points for patient 2. ECAS assessment reveals no evident cognitive 
deficits of patient 1 in either ALS-specific or ALS-nonspecific cognitive domain. Patient 2 
shows unremarkable cognitive skills in ALS-nonspecific domains. ALS-specific cognitive 
functions of patient 1 are estimated divergent in ALS-specific domains, especially in tasks 
concerning speech and verbal fluency. However, these results should be interpreted 
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carefully, as patient 2 is not a native speaker of German. In both patients, ECAS 
assessment was fast (approximately 15min), feasible, and well tolerated by the patients. 
However, scores for speech and verbal fluency may be biased by language skills of non-
native speakers of German.  
The thesis has initially been planned to include a prospective study using the ECAS and 
fMRI. Prolonged data analysis and still limited funding prohibited the conduction of a 
prospective randomized clinical trial (RCT). Thus, the thesis was limited to retrospective 
data acquired since 2010. Results of ECAS exams were incorporated in study 1.   
 
Table 2.1.1 
Scores of ECAS assessment in two patients of the named patient basis treatment program. 
The ECAS includes tasks for so-called ALS-specific domains (language, verbal fluency, 
executive functions) and ALS-nonspecific domains (memory, visuospatial functions). 
 Domains Tasks Patient 1 Patient 2 
ALS-specific Language Naming 
Comprehension 
Spelling 
7/8 
8/8 
12/12 
8/8 
8/8 
4/12 
 Verbal fluency S fluency 
G fluency 
10/12 
12/12 
10/12 
3/12 
 Executive 
functions 
Reverse Digit Span 
Alternation 
Sentence completion 
Social cognition 
12/12 
12/12 
12/12 
12/12 
4/12 
12/12 
10/12 
12/12 
 Total   97/100 71/100 
ALS-nonspecific Memory Immediate recall 
Delayed recall 
Delayed recognition 
7/10 
10/10 
3/4 
4/10 
10/10 
3/4 
 Visuospatial 
functions 
Dot counting 
Cube counting 
Number location 
4/4 
4/4 
4/4 
4/4 
4/4 
4/4 
 Total   32/36 29/36 
Total score   129/136 100/136 
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PROJECT 1: GREY MATTER MORPHOMETRY  
 
Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at 
Baseline and in Longitudinal Courses of Individual Patients with Amyotrophic 
Lateral Sclerosis 
Wirth, A. M., Khomenko, A., Baldaranov, D., Kobor, I., Hsam, O., Grimm, T., 
Johannesen, S., Bruun, T.-H., Schulte-Mattler, W., Greenlee, M. W., Bogdahn, U. 
 
Author-produced version of an article published after peer-review on July 30
th
 2018 in 
Frontiers in Neurology, Frontiers, Lausanne, Switzerland. Reprinted with permission.  
 
ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative process affecting 
upper and lower motor neurons as well as non-motor systems. In this study, precentral and 
postcentral cortical thinning detected by structural magnetic resonance imaging (MRI) 
were combined with clinical (ALS-specific functional rating scale revised, ALSFRS-R) 
and neurophysiological (motor unit number index, MUNIX) biomarkers in both cross-
sectional and longitudinal analyses. The unicenter sample included 20 limb-onset classical 
ALS patients compared to 30 age-related healthy controls. ALS patients were treated with 
standard Riluzole and additional long-term G-CSF (Filgrastim) on a named patient basis 
after written informed consent. Combinatory biomarker use included cortical thickness of 
atlas-based dorsal and ventral subdivisions of the precentral and postcentral cortex, 
ALSFRS-R, and MUNIX for the musculus abductor digiti minimi (ADM) bilaterally. 
Individual cross-sectional analysis investigated individual cortical thinning in ALS patients 
compared to age-related healthy controls in the context of state of disease at initial MRI 
scan. Beyond correlation analysis of biomarkers at cross-sectional group level (n = 20), 
longitudinal monitoring in a subset of slow progressive ALS patients (n = 4) explored 
within-subject temporal dynamics of repeatedly assessed biomarkers in time courses over 
at least 18 months. Cross-sectional analysis demonstrated individually variable states of 
cortical thinning, which was most pronounced in the ventral section of the precentral 
cortex. Correlations of ALSFRS-R with cortical thickness and MUNIX were detected. 
Individual longitudinal biomarker monitoring in four slow progressive ALS patients 
revealed evident differences in individual disease courses and temporal dynamics of the 
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biomarkers. A combinatory use of structural MRI, neurophysiological and clinical 
biomarkers allows for an appropriate and detailed assessment of clinical state and course of 
disease of ALS. 
 
INTRODUCTION 
ALS is a rapidly progressive neurodegenerative disorder affecting upper and lower motor 
neurons as well as non-motor systems (Riva, Agosta, Lunetta, Filippi, & Quattrini, 2016). 
The degeneration of motor neurons results in muscular fasciculation, progressive 
weakness, and eventual paralysis (Calvo et al., 2014). Average survival in ALS is 3–5 
years, but patients evidently vary in phenotype and disease progression (Calvo et al., 2014, 
Rosenfeld & Strong, 2015). The great clinical heterogeneity in ALS is reflected by 
different phenotypes with variability regarding the involvement of UMN and LMN signs, 
site of onset (bulbar, limb), rate of progression, and involvement of neurobehavioral 
deficits (Calvo et al., 2014; Chiò et al., 2011). Therefore, clinical and biological 
biomarkers are helpful in describing disease severity and progression (Rosenfeld & Strong, 
2015). MRI has produced potential biomarkers that clarify the role of brain structure and 
function in the progress of the disease (Agosta et al., 2010; Simon et al., 2014). In 
structural morphometric studies, cortical thickness compared to surface and volume was 
most sensitive to disease-related changes (Turner & Verstraete, 2015). A variety of studies 
investigating structural surface-based morphometry showed reduced cortical thickness 
primarily in the precentral cortex (Agosta et al., 2012; De Albuquerque et al., 2017; Kwan, 
Meoded, Danielian, Wu, & Floeter, 2012; Mezzapesa et al., 2013; Roccatagliata, Bonzano, 
Mancardi, Canepa, & Caponnetto, 2009; Schuster et al., 2013, 2014; Verstraete et al., 
2012; Walhout et al., 2015). Cortical thinning was not restricted to the primary motor 
cortex. Several studies reported cortical thinning to spread to non-motor cortex areas like 
the temporal, frontal, parietal, and postcentral cortex (Agosta et al., 2012; Kwan et al., 
2012; Verstraete et al., 2012). However, not all published MRI studies detected alterations 
in the cortical thickness (Cardenas-Blanco et al., 2016) or cortical volume (Ellis et al., 
2001; Mezzapesa et al., 2007) of the precentral cortex of ALS patients. Essentially, 
precentral cortical thinning was reported to be focal, and dependent on the clinical 
phenotype, rate of progression, and age (Agosta et al., 2012; Mezzapesa et al., 2013; 
Schuster et al., 2013). Additionally, several longitudinal MRI studies revealed no further 
cortical thinning of the precentral cortex in the course of disease (Cardenas-Blanco et al., 
2016; De Albuquerque et al., 2017; Schuster et al., 2014; Verstraete et al., 2012; Walhout 
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et al., 2015). In addition to MRI, clinical and electrophysiological biomarkers are among 
the most currently used and prominent biomarkers (Benatar et al., 2016). The widely used 
ALS-specific functional rating scale revised (ALSFRS-R) and its subscales are correlated 
with survival (Rosenfeld & Strong, 2015). However, correlations between precentral 
cortical thickness and ALSFRS-R scores were rather weak (Cosottini et al., 2016; Kwan et 
al., 2012) or not detected in several neuroimaging studies so far (De Albuquerque et al., 
2017; Roccatagliata et al., 2009; Schuster et al., 2013; Thorns et al., 2013; Walhout et al., 
2015). While MRI is considered a suitable biomarker for UMN function, 
neurophysiological motor unit number estimation (MUNE) and motor unit number index 
(MUNIX) are treated as biomarkers for the estimation of functional lower motor units 
(Stein, Kobor, Bogdahn, & Schulte-Mattler, 2016; Van Es et al., 2017). MUNE is 
calculated from the division of maximal compound muscle action potential (CMAP) by the 
mean surface single motor unit action potential (SMUP) (Gooch et al., 2014). In contrast, 
MUNIX is derived from a mathematical model based on CMAP and electromyographic 
surface interference patterns (SIP) (Grimaldi et al., 2017). MUNE and MUNIX scores are 
inter-correlated in ALS patients (Stein et al., 2016). As the acquisition of MUNIX is easier 
and less time consuming than that of MUNE, MUNIX has become a promising biomarker 
of motor unit loss (Grimm & Schulte-Mattler, 2017; Escorcio-Bezerra et al., 2016). 
MUNIX scores were correlated with ALSFRS-R scores (Grimaldi et al., 2017), but they 
declined faster than ALSFRS-R scores over time in ALS patients (Neuwirth et al., 2017). 
Only few studies investigated the relationship between neurophysiological biomarkers and 
cortical thickness and failed to find a significant correlation with MUNE or other motor 
evoked potential indices (Cosottini et al., 2016; Mitsumoto et al., 2007). To our 
knowledge, no published study investigated correlations between cortical thickness and 
MUNIX as a biomarker potentially affected by both lower and UMN function (Stein et al., 
2016).  
Aim of the study was to investigate individual states of cortical thinning of the precentral 
and postcentral cortex in a limb-onset ALS sample with respect to young-onset, and slow 
disease progression. It is the first study to analyze combinatory biomarker use of MRI 
cortical thickness, neurophysiological MUNIX, and routine ALSFRS-R in both cross 
sectional group analysis of the whole sample, and in longitudinal monitoring exploring 
differences in temporal dynamics between biomarkers in a subgroup of slow progressive 
ALS patients. 
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METHODS 
 
Participants 
Cross-sectional group analysis included 20 limb-onset classical ALS patients (5 females, M 
= 48 years, SD = 11) compared to 30 age-related healthy controls (14 females, M = 45 
years, SD = 13). Mean age of ALS patients was lower than that reported in other ALS 
studies, as the sample included several young-onset patients. Mean ALSFRS-R score 
across all 20 patients at the time point of first MRI scan was 36 score points (SD = 8; 
range: 23–48). The sample included both slow and fast progressive ALS patients indicated 
by disease progression rates (M = 0.51, SD = 0.27; range: 0.00–1.00). The presence of both 
UMN and LMN signs in all patients allowed no clear differentiation in UMN or LMN 
predominance of disease. Patients’ characteristics are summarized in Table 2.2.1. These 
included age (in ranges of years), ALSFRS-R sum scores and neurophysiological MUNIX 
scores for left and right ADM upon initial MRI scan, time interval between symptom onset 
and initial T1 MRI scan (in months), onset of disease (arm, leg), and progression rates 
((48-ALSFRSR)/ months since symptom onset) (Agosta et al., 2012).  
Genetic background of ALS was exhibited in one patient only (patient 8). All other 
patients were diagnosed as sporadic ALS. All patients received standard Riluzole treatment 
and additional G-CSF (granulocyte-colony stimulating factor, Filgrastim) treatment on a 
named patient basis. Application modes and doses of G-CSF were individually adapted, 
treatment duration was up to 7 years. For safety and monitoring of progression, structural 
MRI and MUNIX were assessed every 3 months. ALSFRS-R scores were acquired 
monthly, but were integrated in the analysis only at the time points of MRI scanning. MRI 
cortical thickness was combined with ALSFRS-R sum scores, and MUNIX scores for left 
and right ADM in both cross-sectional analysis and longitudinal biomarker monitoring. 
The unicenter project was carried out in accordance with the Declaration of Helsinki 
(World Medical Association) and approved by the ethics committee at the University of 
Regensburg (ethics approval: 15-101-0106). Written informed consent was obtained prior 
to participation in all participants. 
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Table 2.2.1 
Patients' characteristics at baseline. Summary of characteristics of all 20 limb-onset ALS 
patients including age (in ranges of yrs), ALSFRS-R sum score upon initial MRI scan (48 
in clinical non affected), neurophysiological MUNIX scores for left and right ADM upon 
initial MRI scan, the length of time span between symptom onset and initial MRI scan in 
months, onset of disease (arm, leg), and progression rate. In four out of 20 ALS patients 
(marked with *), neurophysiological assessment was still conducted using MUNE 
technique (patient 4: left MUNE = 2, right MUNE = 1; patient 7: left MUNE =3, MUNE 
right = 77; patient 13: left MUNE = 275, right MUNE = 85; patient 15: left MUNE = 240, 
right MUNE = 120). No MUNIX scores were obtained in these four patients. Progression 
rates were calculated by (48 – ALSFRS-R sum score / months since symptom onset) (see 
Agosta et al., 2012). Neuropsychological assessment using the Edinburgh Cognitive and 
Behavioral ALS Screen (ECAS) was conducted only in patient 3 (129/136 score points) 
and patient 9 (100/136 score points).  
 
# Range 
of age   
ALSFRS-R  
[0 48] 
MUNIX 
Left   
MUNIX            
Right 
Time span 
since  onset 
Onset Progression 
rate 
1 21-25 30     6.63   10.43 49 Arm 0.37 
2 26-30 35     8.20   29.21 28 Arm 0.46 
3 31-35 24     6.94     2.83 28 Leg 0.86 
4 41-45 24 * * 28 Leg 0.86 
5 41-45 41   54.12   38.00 19 Leg 0.37 
6 41-45 28     4.85     0.70 38 Arm 0.53 
7 41-45 46 * * 16 Arm 0.13 
8 46-50 39 138.40   41.88 56 Leg 0.16 
9 46-50 48 170.10 187.30 19 Leg 0.00 
10 46-50 24   48.37   18.51 24 Arm 1.00 
11 46-50 46 213.60 193.00   3 Leg 0.67 
12 46-50 40 114.50   97.18 21 Leg 0.38 
13 46-50 38 * * 25 Leg 0.40 
14 51-55 42   27.25   21.62   7 Arm 0.86 
15 51-55 35 * * 33 Leg 0.39 
16 56-60 38 123.90 101.60 29 Leg 0.34 
17 56-60 44 126.90     0.00 13 Leg 0.31 
18 61-65 42   83.10 119.00 10 Leg 0.60 
19 61-65 24   12.34     9.66 33 Leg 0.73 
20 66-70 21     6.94     2.83 36 Leg  0.75 
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Data acquisition  
Structural MRI was conducted at a 1.5 Tesla clinical scanner (Aera, Siemens Medical, 
Erlangen, Germany). For each patient, a high-resolution T1-weighted structural scan was 
obtained by a magnetization prepared rapid gradient echo sequence (MPRAGE; time-to-
repeat TR: 2220ms, time-to-echo TE: 5.97ms, flip angle FA: 15◦, voxel size: 1 × 1 × 1 
mm3, field of view FOV: 256 × 256 mm², 176 sagittal slices covering the whole brain). 
MUNIX estimates the number of motor units in a muscle by a mathematical algorithm 
involving both the compound muscle action potentials (CMAP) and the continuous 
electromyographic surface interference pattern (SIP) of the muscles (Stein et al., 2016; 
Grimm & Schulte-Mattler, 2017). In contrast to original MUNIX, MUNIX recordings of 
this project implicated continuous SIP recordings during increasing muscle contraction. 
SIP data were modified by baseline correction, filter settings, rectifications, and SIP 
intervals. Artifacts were corrected by exclusion of SIP intervals below a specified baseline 
threshold. As MUNIX was introduced more recently as a neurophysiological biomarker, 
four out of 20 ALS patients received the assessment of MUNE only (see Table 2.2.1). 
 
MRI Data Processing  
T1-weighted structural images were reconstructed by Freesurfer software version 5.3 
(Martinos Center for Biomedical Imaging, Charlestown, MA). The reconstruction 
procedure included automatic segmentation of gray matter and subcortical white matter 
(Fischl et al., 2002) and tessellation and registration of the cortical surface to a spherical 
atlas (Fischl, Sereno, Tootell, & Dale, 1999).). For group analysis, T1- weighted images of 
the 20 individual patients’ brains were registered to the Freesurfer average structural brain 
by using the Freesurfer linear and non-linear image registration tools (FLIRT, FNIRT). 
 
ROI Definition  
Cortical thickness analysis focused on precentral and postcentral regions of interest (ROI) 
as defined by the Desikan-Killiany parcellation atlas (Desikan et al., 2006, see Figure 
2.2.1A). Dorsal and ventral subdivisions of the sensorimotor network were defined by a 
resting-state-functional MRI (fMRI) data-based atlas (Yeo et al., 2011) in volumetric MNI 
(Montreal Neurological Institute) space. These ROIs were subsequently registered to the 
Freesurfer volumetric space and then to the Freesurfer average brain surface (see Figure 
2.2.1B). As all ROIs were mapped upon the Freesurfer average brain space, ROIs were 
identically sized in each patient and healthy control. 
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Computation of Cortical Thickness  
Cortical thickness was computed according to a workflow recommended by Freesurfer 
software. Individual surface-based cortical thickness data were mapped upon the 
Freesurfer average brain surface. By the use of a segmentation statistical tool of Freesurfer 
software, cortical thickness in each of the four ROIs (PreD: precentral dorsal, PreV: 
precentral ventral, PoD: postcentral dorsal, PoV: postcentral ventral, see Figure 2.2.1C) 
was calculated and extracted as a mean value across vertices. 
 
Cross-Sectional Group Analysis 
Group-analysis of mean cortical thickness was conducted using a repeated measures 
ANOVA with the within-subject factors region (PreD, PreV, PoD, PoV) and hemisphere 
(left vs. right), and the between-subject factors group (ALS vs. controls), gender (male vs. 
female), and the covariate age. Differences in cortical thickness between regions were 
investigated by paired t-tests and differences between patients and controls were analyzed 
using independent-samples t-tests. T-tests were corrected by Bonferroni correction. 
Correlation analyses were conducted to investigate relations between cortical thickness, 
ALSFRS-R sum scores and subscores, and MUNIX by the Bravais-Pearson correlation 
coefficient. Significance level was set to p < 0.05. Multiple comparison errors were 
controlled by Bonferroni correction procedure in post-hoc analyses. 
 
Individual Cortical Thickness Analysis 
In addition to cross-sectional group analysis, this project focused on the interindividual 
variability of cortical thinning. For this purpose, we compared the cortical thickness of all 
20 patients to age-related controls, resulting in individual z-transformed deviations of 
cortical thickness from healthy control level. As age effects on cortical thickness are well 
described (Salat et al., 2004), ALS patients were compared to one out of two possible age 
groups. Based on the mean age of ALS patients, the 30 healthy controls were differentiated 
into two comparably sized subgroups (1: age <48 years, n = 17; 2: age ≥48 years, n = 13). 
Furthermore, z-transformed deviations of cortical thickness from healthy controls as well 
as biomarkers MUNIX and ALSFRS-R were monitored in four individual slow 
progressive ALS patients over a time course of at least 18 months (patient 1, 2, 8, 9, see 
Table 2.2.1). All other patients exhibited MRI time courses of a maximum of 9 months 
only (3 scans: n = 2; 2 scans n = 6; 1 scan: n = 8) due to high disability and lack of T1 MRI 
data. 
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Figure 2.2.1. Definition of regions of interest. A) Precentral (red) and postcentral (blue) 
cortex were identified by the Desikan-Killiany parcellation atlas (Desikan et al., 2006). B) 
The resting-state-fMRI based atlas of Yeo et al. (2011) was used to define dorsal (marine 
blue) and ventral (brown) segments of the sensorimotor network (SMN). C) Final 
subdivision of the precentral and postcentral cortex into dorsal and ventral segments 
resulted in four ROIs (precentral dorsal, precentral ventral, postcentral dorsal, postcentral 
ventral) in both left and right hemisphere. ROIs were mapped upon the Freesurfer average 
brain surface. 
 
 
RESULTS 
Cross-Sectional Group Analysis 
As Mauchly’s test indicated that the assumption of sphericity was violated (χ²(5) = 22.42, p 
< 0.001), degrees of freedom were corrected using Greenhouse-Geisser estimates of 
sphericity (ε = 0.79). Cortical thickness was not significantly different between patients 
and healthy controls (F(1, 45) = 1.314; p = 0.258) at cross-sectional group level. Cortical 
thickness significantly varied across cerebral regions (F(3, 135) = 23.351, p < 0.001) and 
with respect to age (F(1, 45) = 21.776, p < 0.001). Cortical thickness was significantly 
higher in precentral than in postcentral regions in both ALS patients (T(19) = 8.584, p < 
0.05, corrected), and healthy controls (T(29) = 16.521, p < 0.05, corrected) (Figure 
2.2.2A). Ventral subdivisions of precentral and postcentral cortex showed greater cortical 
 
 
 
38 
CHAPTER 2: PROJECTS 
thickness than dorsal subdivisions in both ALS patients (T(19) = 9.906, p < 0.05, 
corrected) and healthy controls (T(29) = 12.389; p < 0.05, corrected) (Figure 2.2.2B). 
 
 
Figure 2.2.2. Precentral and postcentral cortical thickness. Cross-sectional analyses of 
cortical thickness of ALS patients (n = 20) and healthy controls (n = 30). A) Precentral 
cortical thickness averaged across left (lh) and right (rh) hemisphere was significantly 
higher than postcentral cortical thickness in both ALS patients and healthy controls. B) 
Cortical thickness of ventral segments of both precentral (PreV) and postcentral (PoV) 
cortex were similarly higher than in dorsal segments (PreD, PoD) in both ALS patients and 
healthy controls. Hemispheric differences were detected only in the precentral (C) and 
precentral ventral cortex (D) of healthy controls. Significance level was set to p < .05. 
Bonferroni correction was used for multiple comparisons. Lh = left hemisphere, Rh = right 
hemisphere, PreV = precentral ventral, PreD = precentral dorsal, PoV = postcentral ventral, 
PoD = postcentral dorsal.  
 
The ANOVA revealed no significant main effect of hemisphere, as significant hemispheric 
differences in cortical thickness were restricted to the precentral (T(29) = 3.445, p < 0.05, 
corrected) (Figure 2.2.2C) and precentral ventral cortex (T(29) = 3.596, p < 0.05, 
corrected) of healthy controls (Figure 2.2.2D). ALSFRS-R sum scores correlated with 
cortical thickness of the precentral ventral cortex (r = 0.570, p = 0.009) and the postcentral 
ventral region (r = 0.481, p = 0.032). Cortical thickness did not significantly correlate with 
MUNIX scores for left and right ADM in any ROI. MUNIX scores for the left (r = 0.767, 
p < 0.05, corrected) and right (r = 0.791, p < 0.05, corrected) ADM correlated with 
ALSFRS-R sum scores. Highest correlations of cortical thickness with ALSFRS-R 
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subscores were found for turning (PreV: r = 0.501, p = 0.024; PoV: r = 0.652, p = 0.002), 
walking (PoV: r = 0.603, p = 0.005), and cutting (PreV: r = 0.453, p = 0.045). MUNIX 
scores predominantly correlated with ALSFRS-R subscores on handwriting (left ADM: r = 
0.637, p = 0.008; right ADM: r = 0.678, p = 0.005), cutting (left ADM: r = 0.840, p < 
0.001; right ADM: r = 0.834, p < 0.001), dressing (left ADM: r = 0.793, p < 0.001, right 
ADM: r = 0.806, p < 0.001), turning (left ADM: r = 0.609, p = 0.012; right ADM: r = 
0.663, p = 0.007), and climbing stairs (left ADM: r = 0.563, p = 0.023; right ADM: r = 
0.611, p = 0.016). ALS patients were separated post-hoc in arm-onset (n = 7) and leg-onset 
(n = 13) groups. Arm-onset patients showed significantly lower MUNIX scores for ADM 
(left: M = 19, SD = 19; right: M = 16, SD = 11) than leg-onset patients (left: M = 95, SD = 
69; right: M = 72, SD = 72) (left ADM: T(14) = −3.399, p < 0.05, corrected; right ADM: 
T(14) = −2.506, p = 0.029). Arm-onset and leg-onset patients did not significantly differ in 
disease progression, ALSFRS-R sum scores and subscores. 
 
Variability of Cortical Thinning  
Thirty healthy controls were differentiated into two groups of age (1. age <48 years, 2. age 
≥48 years, see section Individual Cortical Thickness Analysis). In each of the two 
subgroups, means of cortical thickness of all precentral and postcentral ROIs (see Table 
2.2.2) were calculated.  
 
Table 2.2.2  
References values of cortical thickness. Cortical thickness (mm) of healthy control 
participants subdivided into two age groups (1: age < 48 yrs, 2: age ≥ 48 yrs). Mean age 
of the two subgroups: Group 1: M = 36, SD = 7, n = 17; Group 2: M = 52, SD = 15, n = 
13. Lh = left hemisphere, Rh = right hemisphere, PreV = precentral ventral, PreD = 
precentral dorsal, PoV = postcentral ventral, PoD = postcentral dorsal.  
  Lh PreV 
(mm) 
Rh PreV 
(mm) 
Lh PreD 
(mm) 
Rh PreD 
(mm) 
Lh PoV 
(mm) 
Rh PoV 
(mm) 
Lh PoD 
(mm) 
Rh PoD 
(mm) 
1 M 
SD 
 2.542 
0.205 
2.442 
0.139 
2.106 
0.194 
2.068 
0.158 
2.276  
0.165 
2.205 
0.188 
1.804 
0.158 
1.798 
0.163 
2 M 
SD 
2.249 
0.184 
2.132  
0.275 
1.827 
0.242 
1.807 
0.232 
2.072 
0.198 
2.016 
0.244 
1.663 
0.141 
1.584  
0.145 
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These mean values were used as reference values for the calculation of z-transformed 
deviations of ROI-specific cortical thickness of individual ALS patients (for patient 
numbers see Table 2.2.1) from healthy control level. Cortical thickness alterations below at 
least one deviation from healthy control level were detected in eleven out of twenty 
patients (patients 1, 2, 3, 4, 6, 10, 14, 16, 18, 19, 20) and marginally indicated in two 
patients (patients 5, 9). Cortical thinning was primarily observed in the precentral cortex, 
especially in the ventral segment (Figure 2.2.2A). Most pronounced cortical thinning in all 
precentral ROIs was detected in patient 10 and patient 19. Leg-onset patient 19 was 
characterized by older age (range: 61– 65 years), low ALSFRS-R score (24 score points), 
low MUNIX scores of ADM, and high disease progression rate (0.73). Patient 10 was 
much younger (range: 46–50 years), but showed low ALSFRS-R score (24 score points), 
and the highest progression rate (1.00) of the entire patient sample (see Table 2.2.1). The 
two youngest ALS patients (patients 1–2, age ranges: 21–25 and 26–30 years) shared 
similar patterns of cortical thinning, similar mode of disease (arm-onset), low ALSFRS-R 
scores, low MUNIX scores for ADM, and similar disease progression rates (see Table 
2.2.1, see Figure 2.2.3A). Cortical thinning in the postcentral cortex was detected in four 
patients (patients 9, 10, 19, 20; Figure 2.2.3B). Three out of these four patients also 
exhibited evident precentral cortical thinning. Leg-onset patient 9 stood out of the sample 
with the highest ALSFRS-R score, high MUNIX scores for ADM, lowest progression rate 
(0.00), and more pronounced cortical thinning of the postcentral cortex than of the 
precentral cortex. Increased levels of cortical thickness above healthy control level were 
more prominent in the postcentral cortex than in the precentral cortex. Seven patients 
exhibited unremarkable levels of cortical thickness (patients 7, 8, 11, 12, 13, 15, 17). Six 
(patients 7, 8, 12, 13, 15, 17) out of these seven patients exhibited disease progression rates 
less or equal to 0.40 (see Table 2.2.1). 
 
Longitudinal Monitoring of Cortical Thickness, ALSFRS-R, and MUNIX 
Repeated long-term follow-up T1 MRI data exceeding 18months were available in two 
leg-onset patients (patients 8, 9) and two arm-onset patients (patients 1, 2). The four 
patients presented different initial levels and longitudinal courses of ALSFRS-R sum 
scores (Figure 2.2.4A), MUNIX scores (Figure 2.2.4B), and cortical thickness alterations 
(Figures 2.2.4C–F). Both patients 1 and 2 have in common young-onset (21–30 years), 
arm-onset diagnosis, low levels of ALSFRS-R scores (patient 1: 30 score points, patient 2: 
35 score points) upon first MRI scan, low MUNIX scores for left and right ADM (see 
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Table 2.2.1), and similar progression rates (patient 1: 0.37, patient 2: 0.46). In both 
patients, ALSFRSR sum scores decreased over time (patient 1: blue; patient 2: green; 
Figure 2.2.4A).  
 
 
Figure 2.2.3. Individual variability of cortical thinning in ALS patients. Z-transformed 
deviation of cortical thickness from age-related healthy controls (see Table 2.2.2) in all 20 
individual ALS patients. Patient numbers refer to Table 2.2.1. Patients were sorted by age. 
Z-transformed deviations of cortical thickness were considered relevant at least one 
deviation from healthy controls. A) Individual variability of cortical thickness of the left 
(lh, yellow) and right (rh, red) precentral ventral (PreV) and left (lh, pink) and right (rh, 
purple) precentral dorsal (PreD) ROIs. B) Deviations of individual cortical thickness of the 
left (lh, light green) and right (rh, dark green) postcentral ventral (PoV) and the left (lh, 
bright blue) and right (rh, dark blue) postcentral dorsal (PoD) region in the same 20 
individual patients. Precentral (A) and postcentral (B) ROIs were visualized upon the 
Freesurfer average brain surface. Lh = left hemisphere, Rh = right hemisphere, PreV = 
precentral ventral, PreD = precentral dorsal, PoV = postcentral ventral, PoD = postcentral 
dorsal. 
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Figure 2.2.4. Individual and long-term biomarker monitoring over at least 18 months. 
Arm-onset and young-onset patients (patient 1, 2) showed higher progression rates (see 
Table 2.2.1) than leg-onset similarly aged patients 8 and 9. Patient 9 (yellow), Patient 8 
(red), Patient 2 (green), patient 1 (blue) are sorted based on the initial levels of ALSFRS-R 
sum scores. (A) Courses of ALSFRS-R sum scores of the four individual patients starting 
at different baseline values and developed differently over the measured time span. (B) 
Long-term courses of MUNIX scores for the left and right ADM of the same four patients. 
Individual long-term monitoring of cortical thickness of these four patients in the 
precentral ventral (PreV, C) and dorsal cortex (PreD, D) and postcentral ventral (PoV, E) 
and dorsal (PoD, F) cortex of both hemispheres. Individual cortical thickness is z-
transformed to age-related healthy control level (see Table 2.2.2). Lh = left hemisphere, rh 
= right hemisphere. 
 
In contrast, MUNIX for left and right ADM stagnated at low level (patient 1: blue; patient 
2: green; Figure 2.2.4B). Cortical thickness of the precentral ventral cortex persisted below 
healthy control level over time in both patients (patient 1: blue, patient 2: green; Figure 
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2.2.4C). Cortical thickness of the precentral dorsal cortex decreased below healthy control 
level in patient 1 in the longitudinal course (Figure 2.2.4D). No cortical thinning 
consistently below healthy control level was found for the postcentral ROIs in both 
patients 1 and 2 (Figures 2.2.4E, F). Patient 8 and 9 (both aged 46–50 years) were 
diagnosed with leg onset disease and obtained high ALSFRS-R sum scores at time point of 
initial MRI scan (Table 2.2.1). Progression rates of patient 8 (0.16) and 9 (0.00) were much 
lower than for patients 1 and 2. In both patients, ALSFRS-R sum scores declined over time 
(patient 8: red, patient 9: yellow, Figure 2.2.4A). MUNIX scores of patient 9 similarly 
decreased for the left and right ADM (yellow, Figure 2.2.4B). In patient 8, MUNIX scores 
for the left ADM started at much higher level than for the right ADM and showed a more 
pronounced decline of scores over time (red, Figure 2.2.4B). Patient 8 exhibited 
progressive cortical thinning only in the postcentral ventral cortex (Figure 2.2.4E). In 
patient 9, cortical thinning of the right precentral dorsal cortex spread to the left 
hemisphere over the time course (yellow, Figure 2.2.4D). Cortical thickness of the 
postcentral dorsal cortex further decreased over time (yellow, Figure 2.2.4F). Despite 
fluctuations, ventral sections of precentral and postcentral cortex of patient 9 persisted at 
healthy control level (yellow, Figures 2.2.4C,E). 
 
DISCUSSION 
Cortical thinning was heterogeneous and most pronounced in the precentral ventral cortex. 
ALSFRS-R sum score was associated with both cortical thickness and MUNIX scores. 
Individual longitudinal monitoring of clinical ALSFRS-R, neurophysiological MUNIX, 
and MRI cortical thickness indicated both interindividual differences among ALS patients 
as well as differences in temporal dynamics between biomarkers over the course of 
disease. 
 
Cortical Thickness of the Precentral and Postcentral Cortex 
Cortical thickness was highly age-dependent and significantly different between precentral 
and postcentral cortex as well as between ventral and dorsal subdivisions of precentral and 
postcentral cortex. Postmortem (Meyer et al., 1996) and MRI (Fischl & Dale, 2000; Sahin 
et al., 2016) studies showed approximately 1.5 times greater cortical thickness of the 
precentral compared to the postcentral cortex. The only study addressing gradients of 
postcentral cortical thickness in humans (Wagstyl, Ronan, Goodyer, & Fletcher, 2015) 
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reported greatest cortical thickness in the area defined as ventral segment in our study. Age 
effects on precentral and postcentral cortical thickness have been well described (Salat et 
al., 2004). 
 
Variability of Cortical Thinning 
Individual cross-sectional analysis revealed heterogeneous individual states of cortical 
thinning, which was more pronounced in the precentral than in the postcentral cortex. 
Postcentral cortical thinning was only present in four patients. Three out of these four 
patients also showed pronounced cortical thinning of the precentral cortex. These 
observations are consistent with studies reporting postcentral atrophy was rather less 
prominent or not detectable (Grosskreutz et al., 2006; Roccatagliata et al., 2009). Instead, 
postcentral atrophy was discussed to result from the spread of cortical degeneration in the 
course of disease (Brettschneider et al., 2013; Grosskreutz et al., 2006). With respect to the 
spread of disease, interestingly, individual longitudinal analysis revealed that patient 8 
developed postcentral cortical thinning despite lack of precentral cortical thinning. Cortical 
thinning was most pronounced in the ventral segment of the precentral cortex. The 
precentral ventral cortex as defined here was also reported to exhibit alterations in ALS 
patients in other studies (Lillo et al., 2012; Schuster et al., 2014; Schuster, Hardiman, & 
Bede, 2017). Seven out of twenty patients exhibited no indications of cortical thinning. 
This finding is supported by a meta-analysis reporting cortical atrophy only in a percentage 
of ALS cases (Chen & Ma, 2010) and other MRI studies failing to find alterations in the 
precentral cortex of ALS patients (Cardenas-Blanco et al., 2016; Ellis et al., 2001; 
Mezzapesa et al., 2007). The lack of cortical thinning in ALS patients may be explained by 
low progression rates and young-onset. Cortical thinning was primarily observed in ALS 
patients with faster progression or advanced stage of disease (Meadowcroft et al., 2015). 
Six out of seven patients exhibiting no indications of cortical thinning were characterized 
with disease progression rates less or equal to 0.40. Moreover, the ALS sample of the 
current study was much younger than ALS patients involved in most MRI studies (Agosta 
et al., 2012, 2016; Cardenas-Blanco et al., 2016; Lillo et al., 2012; Schuster et al., 2013; 
Spinelli et al., 2016). Individual cross-sectional analysis also revealed enhanced levels of 
cortical thickness predominantly in the postcentral cortex. Future studies may investigate if 
enhanced levels of cortical thickness may be associated with processes of neuroplasticity 
or treatment effects. Finally, heterogeneous alterations in cortical thickness (including 
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increases and decreases) argue for the need of individual perspective on ALS patients 
beyond group averages (Simon et al., 2014). 
 
Longitudinal Monitoring of Cortical Thickness, ALSFRS-R, and MUNIX 
Longitudinal monitoring of cortical thickness in four patients revealed differences in 
temporal dynamics of clinical ALSFRS-R, neurophysiological MUNIX, and MRI cortical 
thickness in the same individual patients. The long-term biomarker monitoring was limited 
to the patients who survived for longer periods of time and who underwent more than three 
MRI scans. All other patients of the sample received three MRI scans or less due to short 
survival or lack of scan capability. Similar to Abhinav et al. (2014), patients showed very 
different baseline levels and various progression types of ALSFRS-R sum scores over 
time. While the decline of high-level ALSFRS-R sum scores of patient 9 (ALSFRS-R 
baseline: 48) was evidently observable, changes in ALSFRS-R sum scores of progressed 
stage patient 1 (ALSFRS-R baseline: 30) were less evident. These observations are 
consistent with ALSFRS-R being considered to be less sensitive for short-term time 
windows and slow disease progression (Rosenfeld & Strong, 2015; Rutkove, 2015; Van Es 
et al., 2017). ALSFRS-R is also regarded as a rather general severity summary scale 
without sensitivity for mode of disease (Cardenas-Blanco et al., 2016; Neuwirth et al., 
2017). The unspecific character of ALSFRSR may also explain why correlations between 
ALSFRS-R and cortical thickness were weak or not detectable (Cosottini et al., 2016; De 
Albuquerque et al., 2017; Verstraete et al., 2012). In contrast to ALSFRS-R, MUNIX 
significantly differentiated between arm and leg-onset of disease. Corresponding to 
Grimaldi et al. (2017), MUNIX scores significantly correlated with ALSFRS-R scores, but 
showed much faster longitudinal dynamics than ALSFRS-R scores as reported by 
Neuwirth et al. (2017). Once at very low level MUNIX scores stagnated across time in 
arm-onset patients 1 and 2. The phenomenon of a floor effect of MUNIX measurements at 
low level in completely wasted muscles was described by Neuwirth et al. (2015). In 
contrast, higher level MUNIX scores for ADM in leg-onset patients 8 and 9 showed a fast 
decrease over time. Consistent with these observations, clinical markers are considered to 
be more sensitive to changes than MRI markers (Cardenas-Blando et al., 2016). Although 
MUNIX is considered a candidate biomarker like MUNE for LMN function (Van Es et al., 
2017), MUNIX scores may be influenced by both lower and UMN function (Stein et al., 
2016). Existing studies investigating correlations of cortical thickness to MUNE or other 
neurophysiological techniques failed to find significant correlations (Cosottini et al., 2016; 
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Mitsumoto et al., 2007). As the first study combining MRI cortical thickness with MUNIX, 
we also found no significant correlations. Differences in both individual state of disease 
and within-subject temporal dynamics of various biomarkers may explain the difficulty to 
find significant correlations in multimodal biomarker use. 
 
Methodological limitations 
Some methodological limitations need to be considered. First, the sample size was limited 
to 20 patients. As ALS MRI studies suffer from high costs and high drop-out rates due to 
increasing disability of patients (Rutkove, 2015), many published unicenter ALS MRI 
studies included samples smaller than 20 ALS patients (Cosottini et al., 2013; Grosskreutz 
et al., 2006; Roccatagliata et al., 2009; Verstraete et al., 2010). Second, the MRI magnetic 
field strength was 1.5T. Although MRI magnetic field strength of 3T may have been 
beneficial, 1.5T still was sufficient for the detection of gray matter alterations in ALS MRI 
studies (Grosskreutz et al., 2006; Mezzapesa et al., 2013; Roccatagliata et al., 2009; 
Tavazzi et al., 2015; Thorns et al., 2013). Third, by the use of a more conservative ROI 
based approach than a vertex-based approach, the study may have failed to detect very 
focal cortical thinning inside of the ROIs. However, this approach did not only reduce the 
influence of false positive results but still successfully detected cortical thinning. Fourth, 
MUNIX scores were not assessed in leg muscles. However, this study is the first cross-
sectional and longitudinal study combining cortical thickness analysis with both ALSFRS-
R and MUNIX with respect to the individual patient. Fifth, longitudinal monitoring of 
biomarkers was limited to four patients of the sample due to high disability (n = 6), death 
(n = 4), lack of T1 data (n = 6). Still, our long term biomarker monitoring analysis is 
unique, as to our knowledge, none of the published longitudinal MRI studies showed 
longitudinal courses of both MRI cortical thickness and MUNIX biomarkers using as many 
repeated measures in a time course longer than 18 months as presented in the current study. 
Moreover, most MRI studies focused on group analysis irrespective of the individual 
patient (Cardenas-Blanco et al., 2016; De Albuquerque et al., 2017; Kwan et al., 2012; 
Schuster et al., 2014; Verstraete et al., 2012; Walhout et al., 2015), although the individual 
perspective has been increasingly demanded in ALS neuroimaging research (Simon et al., 
2014; Turner et al., 2013; Van Es et al., 2017; Verstraete & Foerster, 2015).  
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CONCLUSIONS 
The present study demonstrated that MRI is a potential biomarker for the differentiation of 
individual states of cortical thinning in an ALS sample including young-onset and slow 
progressive patients. Longitudinal monitoring of MRI, clinical, and neurophysiological 
biomarkers in the same patient reveal substantial differences in temporal dynamics. 
Combinatory biomarker use contributes a substantial gain of information about individual 
state of disease beyond group averages. Future studies may expand the idea of combining 
neuroimaging techniques with other clinical or molecular biomarkers to deepen our 
understanding of multisystem/multifactorial ALS disease progression. 
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PROJECT 2: WHITE MATTER DIFFUSION PROPERTIES      
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anisotropy in classical Amyotrophic Lateral Sclerosis 
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ABSTRACT 
Background:  Dying-forward and dying-back hypotheses propose different origins of the 
pathology of amyotrophic lateral sclerosis (ALS). The aim of this study was to investigate 
these hypotheses by fractional anisotropy (FA) of different white matter (WM) types in 
magnetic resonance imaging (MRI): brainstem WM (BS), projection fibers (PF), 
association fibers (AF), and commissural fibers (CF).  
Methods: Diffusion-weighted imaging (DWI) data were acquired in 28 limb-onset classical 
ALS patients (9 females, mean age = 49 yrs, SD = 12yrs, mean ALSFRS-R score: 38, 
range: 21-48, mean disease progression rate: 0.89) and 34 age-related healthy controls (14 
females, M = 45 yrs, SD = 12yrs). ALS patients were treated with standard Riluzole and 
additional long-term G-CSF (Granulocyte-Colony Stimulating Factor, Filgrastim) on a 
named patient basis with written informed consent. For safety and monitoring, MRI was 
conducted approximately every three months. Patients’ raw FA values of 48 atlas-based 
WM ROIs were compared to the most suitable of two age groups of healthy controls 
resulting in z-transformed deviations. Alterations in FA of BS, PF, AF, and CF were 
investigated at baseline (n = 28) and in the longitudinal course of disease (n = 24). 
Propagation of FA alterations across WM types was associated with clinical data.   
Results: FA alterations at initial MRI scan were significantly specific to region and type of 
WM. Most pronounced FA alterations were observed in the BS. Individual perspectives as 
well as group analysis revealed the spread of FA alterations across all WM types, 
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reflecting both cortico-fugal and cortico-petal propagation of disease. Patterns of spread 
resembling either dying-back or dying-forward processes were not significantly linked to 
ALSFRS-R, disease progression, onset of ALS, survival, age or gender.  
Conclusions: Spread of FA alterations across WM types may serve as a biomarker for 
differentiation of dying-forward or dying-back propagation in classical ALS.   
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease affecting both 
upper (UMN) and lower motor neurons (LMN) and non-motor systems (Al-Chalabi et al., 
2016). ALS patients display a broad range of phenotypes including weakness and wasting 
of muscles and spasticity (Morgan & Orrell, 2016) as well as deficits in cognition and 
behavior (Ravits et al., 2013). Neither disease etiology nor pathogenesis is fully understood 
(Morgan & Orrell, 2016), and the development of pathological changes as either dying-
forward or dying-back is a matter of discussion (Kiernan et al., 2011). The dying-back 
hypothesis indicates the origin of ALS in the LMN and neuromuscular junctions. The 
retrograde degeneration was supported by synaptic denervation processes before clinical 
onset of motor neuron degeneration (Chou & Norris, 1993). The dying-forward hypothesis 
proposes the origin of ALS in the UMN. The anterograde degeneration process is endorsed 
by cortical hyperexcitability in early stage ALS (Vucic et al., 2012). Dying-back and 
dying-forward processes may also occur independently (Kiernan et al., 2011). 
MRI fractional anisotropy (FA) is considered a prominent biomarker for the estimation of 
WM integrity (Chiò et al., 2014). Alterations of FA were most consistently observed in the 
corticospinal tract, especially in the corona radiata, posterior limb of capsula interna, 
cerebral peduncles, and the pons (see review by Grolez et al., 2016). Moreover, FA 
alterations were reported in the cerebellum and extramotor areas such as corpus callosum, 
thalamic radiation, fornix, cingulum, and superior longitudinal fasciculus (Chapman, 
Jelsone-Swain, Johnson, Gruis, & Welsh, 2014; Douaud, Filippini, Knight, Talbot, & 
Turner, 2011; Filippini et al., 2010; Keil et al., 2012; Sach et al., 2004; Van der Graaff et 
al., 2011). Kassubek et al. (2014, 2017) proposed a four-stage (corticospinal tract, 
corticorubral/corticopontine pathway, corticostriatal pathway, perforant pathway) 
Diffusion tensor imaging (DTI)-model of WM degeneration based on the sequential spread 
of protein aggregations in post-mortem studies (Brettschneider et al., 2013). To date, the 
relevance of different functional types of WM tracts in ALS remains unclear: brainstem 
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WM (BS), projection fibers (PF), association fibers (AF), and commissural fibers (CF). Of 
these, CF are inter-hemispheric, whereas PF and AF are intra-hemispheric connections 
(Aralasmak et al., 2006). While PF connect subcortical with cortical areas, AF provide 
connections between cortical areas.  
The aim of the study was to investigate FA alterations of different WM types at baseline 
and during disease progression. Patterns of spread of WM type degeneration were 
associated with clinical data of ALS patients. These analyses should then clarify the type 
and character of spread of disease in ALS. 
 
METHODS 
Participants 
The uni-center project was carried out in accordance with the Declaration of Helsinki 
(World Medical Association) and approved by the ethics committee at the University of 
Regensburg (ethics approval: 15-101-0106). Written informed consent was obtained prior 
to participation. The sample included 28 limb-onset classical ALS patients (9 females, 
mean age = 49 yrs, SD = 12) compared to 34 age-related healthy controls (14 females, 
mean age = 45 yrs, SD = 12). Mean ALSFRS-R score at initial MRI scan was 38 (range: 
21-48). Mean disease progression rate ((48 – ALSFRS-R score) / months since symptom 
onset) was 0.89 (range: 0 – 6.0). Characteristics of ALS patients including range of age, 
ALSFRS-R scores at baseline, time span between symptom onset and initial MRI, 
progression rate at baseline, and number of MRI scans are listed in Table 2.3.1. Genetic 
background of ALS was confirmed in one patient only (patient 7). All other ALS patients 
of the sample were diagnosed with sporadic ALS. Patients received standard Riluzole and 
additional G-CSF (granulocyte-colony stimulating factor, Filgrastim) treatment on a 
named patient basis from 2010 to present (Grassinger et al., 2014). Application modes and 
doses of G-CSF were individually adapted.  Treatment duration was up to seven years. For 
safety and monitoring of progression, structural MRI data were assessed approximately 
every three months. ALSFRS-R scores were evaluated monthly. Repeated MRI scans were 
assessed in 24 patients. Different individual lengths of longitudinal courses in these 24 
patients were indicated by different amounts of MRI scans (mean MRI time course: 16 
months, range: 3 – 75 months, see Table 2.3.1). Four patients were not able to participate 
in more than one MRI scan due to high disability.  
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Table 2.3.1  
Baseline characteristics of patients. Characteristics include range of age, ALSFRS-R sum 
score at initial MRI scan, time interval between symptom onset and initial MRI scan, 
progression rate ((48 – ALSFRS-R score at initial MRI scan) / months since symptom 
onset), and total number of MRI scans. DWI sequence change affected 17 out of 28 
patients (*). In these patients, sequence-derived biases of FA raw values were corrected by 
multiplication factors.  
# Age  
[range] 
ALSFRS-R  
[0 48] 
Time symptom 
onset – first MRI 
scan [months]      
Progression 
rate 
 
Number  
of scans 
Sequence 
change 
  1 26-30 33 22 0.68 19 * 
  2 26-30 44 7 0.57 12 * 
  3 31-35 36 8 1.50   2 * 
  4 31-35 24 28 0.86   2  
  5 41-45 32 28 0.57   8 * 
  6 41-45 37 36 0.30   7 * 
  7 41-45 44 38 0.10 11 * 
  8 41-45 42 13 0.46   3  
  9 41-45 48 19 0.00 12  
10 41-45 44 16 0.25   6 * 
11 41-45 28 38 0.53   1  
12 46-50 29 20 0.95   2  
13 46-50 46 3 0.67   4 * 
14 46-50 31 5 3.40   2 * 
15 46-50 42 25 0.24   5 * 
16 46-50 40 21 0.38   2  
17 46-50 33 60 0.25   1 * 
18 51-55 42 7 0.86   2  
19 51-55 37 33 0.33   4 * 
20 56-60 39 23 0.39   2  
21 56-60 48 14 0.00   6 * 
22 61-65 41 12 0.58   4 * 
23 61-65 42 3 2.00   3  
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24 61-65 44 14 0.28   2  
25 61-65 29 16 1.19   1 * 
26 66-70 36 2 6.00   2 * 
27 66-70 21 26 1.04   1  
28 71-75 45 25 0.12   2 * 
 
Data acquisition 
Structural MRI was conducted at two 1.5 Tesla clinical scanners (Aera, Sonata, Siemens 
Medical, Erlangen, Germany). DWI data were acquired with single shot spin-echo echo-
planar sequences. The initial diffusion sequence of six orientations (DWI6) (repetition time 
TR: 3500 ms, echo time TE: 83 ms, flip angle FA: 90°, field of view FOV: 230 x 230 mm, 
5 mm slice thickness, 20 axial slices, b-value: 1000 s/mm², three b0 images) was modified 
to 20 orientations (DWI20) (TR: 3500 ms, TE: 83 ms, FA: 90°, FOV: 230 x 230mm, 5 mm 
slice thickness, 20 axial slices, b-value: 1000 s/mm², three b0 images) during data 
acquisition period. Possible biases caused by the change of DWI sequence were controlled 
for and corrected by a separate control analysis.  
 
Data preprocessing 
MRI data of both ALS patients and healthy controls were processed by a workflow (Figure 
2.3.1) using Freesurfer software 5.3 (Martinos Center for biomedical imaging, Charlestown, 
MA) and Matlab (Release 2012b, The MathWorks, Inc., Natick, Massachusetts, United 
States). DWI raw data were preprocessed and atlas-based ROIs were registered to 
individual DWI space (Figure 2.3.1A). Maps of DTI-based FA were estimated (Figure 
2.3.1B). The Johns Hopkins University (JHU) WM atlas by Mori et al. (2008) defined 48 
WM regions in Montreal Neurological Institute (MNI) DWI space (resolution: 2mm). 
Average DWI space was registered to individual DWI space by using linear and nonlinear 
registration tools (FLIRT, FNIRT). Registrations were visually inspected and carefully 
adapted if necessary. All 48 WM regions were transferred to the individual DWI space. 
Mean FA values for all regions were calculated across voxels in every individual patient 
and healthy control. 
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Figure 2.3.1. DWI workflow. A) Preprocessing of raw DWI data of both ALS patients (n = 
28) and healthy controls (n = 34). Individual maps of FA were estimated based on DTI 
model. 48 atlas-based WM regions (Mori et al., 2008) were registered to the individual 
DWI space. B) Extraction of means of FA across voxels for each of the 48 WM regions. 
Healthy controls (n = 34) were differentiated into two reference age control groups. FA 
values of ALS patients for every WM region were compared to reference values of FA of 
the adequate control group resulting in z-transformed deviations. C) The 48 WM regions 
were differentiated into four WM types (BS, PF, AF, CF) based on Mori et al. (2008). The 
WM type ROIs including all 48 regions were modified by using only regions with FA 
alterations significantly below healthy control level (one-sample t-test) (see Table 2.3.2). D) 
The resulting specified WM type ROIs were used for baseline (n = 28) and longitudinal (n 
= 24) analyses with respect to both group level and individual patient. 
 
Sequence-derived biases on fractional anisotropy 
A subset of healthy controls (n = 22) was involved in a separate control analysis. These 22 
healthy controls were assessed with both DWI sequences (DWI6, DWI20) on the same 
acquisition day. We calculated FA of the 48 WM regions in both DWI data sets. Possible 
bias effects of DWI sequence (DWI6, DWI20) were analyzed by a repeated-measures 
ANOVA. Raw FA values of DWI20 sequence were divided by raw FA values of DWI6 
sequence resulting in one multiplication factor for every WM region. This multiplication 
factor enabled the correction of sequence-derived biases of FA in the 17 patients (see Table 
2.3.1) assessed with DWI6 sequence. In all other patients, DWI20 sequence was 
consistently used and no FA correction was necessary.  
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Calculation of WM type-specific fractional anisotropy  
ALS patients (n = 28) were compared to the whole sample of healthy controls (n = 34). 
Healthy controls were signed into two reference age control groups (Group 1: < 49 yrs, n = 
20; Group 2: age ≥ 49 yrs, n = 14) (Figure 2.3.1B). In both groups, means of FA for every 
WM region served as reference values for the calculations of z-transformed deviations of 
FA of ALS patients from healthy control level. The differentiation of 48 regions into BS 
(corticospinal tract, pontine crossing tract, medial lemniscus, cerebellar peduncles), PF 
(capsula interna, corona radiata, cerebral peduncles, posterior thalamic radiation), AF 
(capsula externa, sagittal stratum, cingulum, superior longitudinal fasciculi, superior 
frontooccipital fasciculi, uncinate fasciculi, fornix) and CF (genu, body, splenium, tapetum) 
was based on Mori et al. (2008). For every WM type, medians of z-transformed deviations 
of FA alterations across the referred regions were calculated (Figure 2.3.1C). After the 
investigation of region-specific FA alterations, ROI definitions of the four WM types by all 
48 WM regions were modified by only taking into account regions with FA alterations 
significant below zero (one sample t-tests, n = 28). FA alterations of the four WM types in 
ALS patients were analyzed at the time point of initial MRI scan (n = 28) and during 
disease progression (n = 24) at both group level and individual level (Figure 2.3.1D). 
 
WM type-specific alterations of fractional anisotropy at baseline 
Repeated-measures ANOVAs were used to investigate differences in ALS patients’ z-
transformed deviations of FA between different regions or types of WM (within-subject 
factors). Both ANOVAs included between-subject factor gender and covariate age. 
Individual perspective enabled the investigation of variability of WM type-specific FA 
alterations across patients.  
 
Spread of WM type-specific FA alterations over time 
Longitudinal FA analysis included 24 out of 28 patients. Four out of 28 patients were not 
able to participate in follow-up MRI due to high disability. Longitudinal courses of FA 
alterations of the four different WM types were assessed by the calculation of slopes of FA 
over time. Patients (n = 24) were divided in low level (z-deviation < -1) and normal level 
(z-deviation > -1) baseline FA alterations for most affected WM types. A repeated-
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measures ANOVA including within-subject factor WM type (BS, PF, AF, CF), and 
between-subject factors baseline level of  FA alterations (low, normal) and gender, and 
covariates age and time span of MRI follow-up helped to investigate potential effects of 
baseline FA levels on slopes of WM type-specific FA alterations over time. Significance 
levels of group analyses were set to p < .05. At individual level, spread of FA alterations 
across WM types was inspected for every single patient. Based on these patterns, patients 
were differentiated into either dying-back or dying-forward groups. Independent t-tests and 
chi-square tests for independence served to investigate differences in demographic and 
clinical characteristics between those two groups.  
 
RESULTS 
Control analysis of sequence-derived biases on FA 
FA values for DWI20 sequence were significantly higher than those for DWI6 sequence 
consistently across all 48 WM regions (F(1, 21) = 1019.11, p < .001, n = 22 healthy 
controls). We corrected the sequence-derived bias of FA values by the calculation of a 
multiplication factor for every WM region, and thus were able to raise FA values of DWI6 
to the level of DWI20. After this correction, the initial DWI sequence effect was no longer 
significant (F(1, 21) = 0.447, p = .511).   
 
Region-specific and WM type-specific FA alterations at baseline 
Deviations of FA of ALS patients from healthy control level were significantly specific to 
WM regions (F(47, 1175) = 1.912, p < .001). Repeated-measures ANOVA revealed no 
significant effects of gender (F(1,25) = 2.693, p = .113) or covariate age (F(1, 25) = 0.998, 
p = .327). Baseline FA alterations significantly below healthy control level were detected 
in specific WM regions of the BS, PF, AF, and CF (Table 2.3.2). Significant BS alterations 
involved the pontine crossing tract, the corticospinal tract, and the inferior cerebellar 
peduncles of the left and right hemispheres. Most pronounced FA alterations in the PF 
were observed in the bilateral cerebral peduncles and the posterior thalamic radiation. 
Alterations in AF were primarily detected in the fornix, the sagittal stratum, and the 
frontooccipital longitudinal fasciculus of the left hemisphere. Most affected WM regions of 
CF were callosal body and the left tapetum. ROIs of WM types (BS, PF, AF, CF) were 
redefined by taking into account only the WM regions listed in Table 2.3.2.  
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Table 2.3.2  
Region-specific FA alterations at baseline. One-sample t-test (n = 28) testing FA 
alterations below threshold 0. BS = brainstem tracts, PF = projection fibers, AF = 
association fibers, CF = Commissural fibers, lh = left hemisphere, rh = right hemisphere.  
P-values refer to z-transformed deviations of FA significantly below zero at initial MRI 
scan. Significance level is set to p < .05 (uncorrected). 
Type ROI T  p 
BS Pontine crossing tract  -3.580    .001 
 Corticospinal tract rh -7.277 < .001 
 Corticospinal tract lh -6.460 < .001 
 Inferior cerebellar peduncle rh -5.284 < .001 
 Inferior cerebellar peduncle lh -6.027 < .001 
PF Cerebral peduncle rh -3.408    .002 
 Cerebral peduncle lh -4.796 < .001 
 Posterior thalamic radiation rh -3.675    .001 
 Posterior thalamic radiation lh -2.619    .014 
AF Fornix -4.028 < .001 
 Sagittal stratum lh -3.278    .003 
 Superior frontooccipital fasciculus lh -3.996 < .001 
CF Body -2.571    .016 
 Tapetum lh -2.546        .017 
 
A repeated-measures ANOVA considering both initial and redefined WM type ROIs 
(Figure 2.3.2A) served as a control analysis. Modification of the WM type ROIs (BS, PF, 
AF, CF) by only ALS-relevant WM regions instead of using all 48 WM regions 
significantly improved the accuracy of detecting FA alterations, especially in the BS (T(27) 
= 5.239, p < .001), PF (T(27)= 6.294, p < .001), and CF (T(27) = 4.439, p < .001) (F(3, 75) 
= 4.687, p = .005) (Figure 2.3.2B). In both ROI models, FA alterations significantly 
differed between WM types (F(3, 75) = 2.724, p = .05). A separate repeated-measures 
ANOVA focusing on only redefined WM ROIs underlined the specificity of FA alterations 
to WM types (F(3, 75) = 2.997, p = .036). Deviations of FA of ALS patients from healthy 
control level were most pronounced in the BS (Figure 2.3.2B). No significant effects of 
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gender (F(1, 25) = 3.728, p = .065) or covariate age (F(1, 25) = 1.299, p = .265) were 
detected. Correlation analyses revealed rather weak or no significant correlations of WM 
type-specific FA alterations with baseline ALSFRS-R scores (BS: r = -.148, p = .454; PF: r 
= -.080, p = .687; AF: r = -.058, p = .770; CF: r = .148, p = .451) or disease progression 
rates (BS: r = -.025, p = .900; PF: r = -.374, p = .050; AF: r = -.107, p = .589; CF: r = -
.125, p = .527). 
 
Individual alterations of fractional anisotropy at baseline  
Individual patient analysis revealed different states of FA alterations at baseline level 
(Figure 2.3.2C). The majority (n = 19) of 28 patients showed reduced FA baseline levels 
involving BS only (n = 3; patients 17, 18, 19), BS + PF only (n = 3, patients 1, 12, 20), BS 
+ PF + AF only (n = 4; patients 2, 3, 21, 24), or in all four WM types as BS + PF + AF + 
CF (n = 9, patients 5, 7, 9, 10, 14, 22, 25, 26, 28). However, some patients showed 
alternative deviation patterns (n = 7, patients 4, 6, 8, 11, 15, 23, 27) or no FA alterations (n 
= 2, patients 13, 16) at baseline: Both patients without FA alterations exhibited ALSFRS-R 
scores higher than 40 scores points. Four out of the seven patients with alternative 
deviation patterns (patient 6: PF+CF, patient 8: BS + CF, patient 11: CF, patient 15: PF) 
shared low progression rates (range: 0.24 - 0.53). The other three patients (patients 4, 23, 
27) exhibited particular clinical characteristics. Young-onset patient 4 showed FA 
alterations in the BS and AF, low ALSFRS-R score (24 score points) and average disease 
progression (0.86). Patient 23 exhibited FA alterations in all WM types except for the AF 
and fast disease progression (2.00). Patient 27 stood out of the sample by FA alterations in 
all WM types except for the BS, low ALSFRS-R score (21 score points), fast disease 
progression (1.04), and a time course of 26 months since symptom onset.  
 
Spread of alterations of fractional anisotropy across WM types  
We acquired longitudinal MRI data in 24 out of 28 patients. A repeated-measures ANOVA 
(within-subject factor: WM type; between-subject factors: baseline FA alterations of BS 
and PF, gender; covariates: age, time span of MRI follow-up) revealed no significant 
differences of slopes of FA alterations between WM types (F(3, 42) = 1.768, p = .168). 
Instead, slopes of WM type-specific FA significantly depended on age (F(1,14) = 9.795, p 
= .007), time span of MRI follow-up (F(1, 14) = 7.829, p = .014) and baseline levels of FA 
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alterations in the PF (F(1, 14) = 5.702, p = .032). In contrast, baseline levels of FA 
deviations in the BS had no significant impact on slopes of WM type-specific FA over 
time (F(1, 14) = 0.066, p = .801). Slopes of WM type-specific FA alterations did not 
significantly correlate with slopes of ALSFRS-R scores over time (BS: r = -.087, p = .685; 
PF: r = .075, p = .728; AF: r = .131, p = .540; CF: r = .026, p = .906).  
 
Dying-back and Dying-forward in the context of clinical data 
Individual courses of FA alterations over time were inspected for every single patient. 
Spread of FA alterations across WM types was observed in mainly two patterns resembling 
dying-back or dying-forward. Patient 2 is visualized as an example for potential dying-
back propagation (Figure 2.3.2D). Here, FA alterations were most pronounced in the BS 
and propagated to PF, AF, and C. This pattern of FA decline was observed in 13 out of 24 
patients with longitudinal courses. Ten out of 24 patients showed patterns of spread 
resembling dying-forward patterns as visualized in exemplary patient 9 (Figure 2.3.2E). 
This pattern of spread was characterized by no primary involvement of BS alterations 
(Figure 2.3.2E) but rather predominant FA alterations in the PF and CF. Fluctuations in FA 
hindered the classification of patient 13 (see Table 2.3.1) into one of the two groups. 
Patient groups of dying-back (n = 13) and dying-forward (n = 10) did not significantly 
differ in age (T(21) = -1.648, p = .117), baseline ALSFRS-R score (T(21) = -0.599, p = 
.555), ALSFRS-R slope over time (T(21) = 1.533, p = .142), or disease progression rate at 
baseline (T(21) = -0.903, p = .384). Patterns of spread were specific to neither gender 
(χ2(1) = 0.710, p = .400, φ = .176) or onset site (χ2(1) = 0.006, p = .940, φ = .016). 
Moreover, patients with different spread of FA did not significantly differ in survival since 
initial MRI scan (T(15) = 0.693, p = .502). Survival analysis was restricted to a sample size 
of n = 17 instead of n = 23, as six patients were alive and still participating in the study.  
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Figure 2.3.2. WM type-specific FA alterations. A) ROIs of WM types were defined by 
either all 48 atlas-based WM regions or only by regions with significant FA alterations 
below zero. B) FA alterations of WM types before and after ROI modification at baseline 
in 28 patients. C) Individual states of FA alterations at baseline level of 28 patients. Patient 
numbers refer to Table 2.3.1. Threshold for visualization of FA alterations (BS: blue, PF: 
pink, AF: red, CF: yellow) is -0.5. Longitudinal analysis differentiated patients (n = 24) 
into either dying-back (see patient 2, D) or dying-forward (see patient 9, E) patterns of 
spread. FA alterations are described by z-transformed deviations from healthy control level 
(zero, black line). Colors refer to BS (brainstem WM, blue), PF (projection fibers, pink), 
AF (association fibers, red), and CF (commissural fibers, yellow). 
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DISCUSSION 
FA alterations of WM were specific to regions and types of WM in ALS patients. 
Compared to values from age-related controls, the most pronounced baseline FA 
alterations of ALS patients were detected in the BS. A spread of FA alterations between 
WM types was supported by both individual perspective and group analysis. Patients with 
classical ALS showed both dying-back and dying-forward patterns.  
FA alterations in the WM of ALS patients compared to healthy controls were region-
specific. This is consistent with the literature. At the BS level, significantly reduced FA 
levels of ALS patients compared to healthy controls were observed in the pontine crossing 
tract, corticospinal tract and inferior cerebellar peduncles as reported in several previous 
studies (Douaud et al., 2011; Karlsborg et al., 2004; Keil et al., 2012; Roccatagliata et al., 
2009; Sach et al., 2004; Sage, Peeters, Görner, Robberecht, & Sunaert, 2007; Toosy et al., 
2003). At PF level, FA alterations were detected in the cerebral peduncles and the posterior 
thalamic radiation. Observations of reduced FA of ALS patients in the cerebral peduncles 
(Metwalli et al., 2010; Prudlo et al., 2012; Roccatagliata et al., 2009) and in the thalamic 
radiations (Douaud et al., 2011; Prudlo et al., 2012) have been published. At AF level, we 
observed FA alterations in the fornix, sagittal stratum and the superior frontooccipital 
fasciculus. AF like fornix and longitudinal fasciculi were altered in ALS patients (Borsodi 
et al., 2017; Chapman et al., 2014; Prudlo et al., 2012; Sarica et al., 2014; Van der Graaff 
et al., 2011). Reduced FA in CF, especially in the callosal body, was frequently described 
(Chapman et al., 2014; Douaud et al., 2011; Filippini et al., 2010; Keil et al., 2012; 
Metwalli et al., 2010; Menke et al., 2012; Prudlo et al., 2012; Sach et al., 2004). The 
tapetum is defined as an area of the corpus callosum involving fibers of the splenium along 
the lateral ventricle (Sarikcioglu, Ozsoy, & Unver, 2007), but its structural and functional 
role is poorly understood.  
Baseline FA alterations significantly depended on WM type and were most pronounced in 
the BS. This finding may support the dying-back hypothesis. However, individual 
perspective on every single ALS patient's WM type specific FA alterations at baseline 
revealed patterns of FA alterations without BS involvement (n = 7) or no FA alterations at 
all (n = 2). The absence of FA alterations could have different reasons such as early stage 
ALS, slow progression, dying-back process originating from the spinal cord (Nair et al., 
2010) or by reduced sensitivity of method. As the WM atlas did not include cortex adjacent 
areas (e.g. motor cortex), the analysis may not directly endorse a cortical origin of 
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degeneration (dying-forward). Slopes of WM type-specific FA alterations significantly 
depended on age, time span of MRI follow-up and baseline levels of PF. Although FA is 
considered to be less susceptible to age effects than cortical thickness (Pfefferbaum, 
Adalsteinsson, Rohlfing, & Sullivan, 2008), age may be an important prognostic factor in 
ALS (Chiò et al., 2009). Meta-analysis of Zhang et al. (2018) reported no significant 
correlations between age and FA decrease. Age effects in our study may be explained by 
the broad range of age in an ALS sample including also young-onset patients. Length of 
MRI follow-up was replicated to be crucial as it may bias results of longitudinal MRI 
studies by slow-progressive cases (Menke, Proudfoot, Talbot, & Turner, 2017). BS 
alterations at baseline were observed in the majority of ALS patients but were no crucial 
factor for slopes of FA of other WM types over time. As reported in other studies (Borsodi 
et al., 2017; Roccatagliata et al., 2009; Sage et al., 2007; Toosy et al., 2003) FA alterations 
at baseline and their slopes over time did not significantly correlate with ALSFRS-R scores 
themselves or disease progression rates derived from ALSFRS-R scores. The lack of 
correlation may be explained by the influence of not only UMN but also LMN 
involvement on ALSFRS-R scores (Simon et al., 2014), whereas MRI may predominantly 
reflect UMN affection. Moreover, lack of correlations may be explained by the suggestion 
that ALSFRS-R may be more sensitive for disease-related changes than diffusion 
properties (Cardenas-Blanco et al., 2016).  
13 out of 24 ALS patients showed longitudinal spread of FA alterations resembling dying-
back. In these patients, BS involvement preceded FA alterations of other WM types. In 10 
out of 24 patients, FA alterations were more pronounced in the PF, AF, and C without 
primary involvement of BS. One patient could not be sorted in either dying-forward or 
dying-back patterns of spread due to high fluctuations of FA alterations. Fluctuations of 
FA deviations of WM types may result from data quality or focal FA alterations within 
WM types. ALS patients with different spread of FA alterations did not significantly differ 
in age, ALSFRS-R baseline or slope, disease progression rate, and survival. Moreover, 
dying-back or dying-forward propagation of FA alterations were not associated with 
gender or onset of disease. These findings indicate that both patterns of spread may 
independently exist in classical ALS (Kiernan et al., 2011).   
Some methodological limitations need to be considered. First, sample size was limited to 
28 ALS patients. Still, sample sizes of 20-30 patients were shown to be adequate for MRI 
analysis in unicenter ALS studies published since 2010 (Borsodi et al., 2017; Douaud et al., 
2011; Fillippi et al., 2010; Keil et al., 2012; Metwalli et al., 2010). Second, slice thickness 
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of DWI sequence was relatively large. Facing this issue, we chose a ROI approach using 
larger atlas-based ROI definitions (Mori et al., 2008) instead of voxel-based approaches or 
fiber tractography. Third, DWI sequence was changed during the period of data acquisition. 
When dealing with different MRI scanners, FA is the most robust DTI estimate (Fox et al., 
2012). We replicated sequence-derived biases on FA values (Wang, Abdi, Bakhadirov, 
Diaz-Arrastia, & Devous, 2011) and corrected these biases by a separate control analysis. 
As the study design included no ALS control sample without G-CSF treatment, therapeutic 
effects may not be deduced from this study.  
 
Conclusions 
We demonstrated that FA alterations of WM in limb-onset ALS patients are specific to 
both region and type of WM. They were most pronounced in the BS. FA decline spread 
between different WM types indicating retro- and anterograde patterns of spread 
supporting both dying-forward and dying-back hypotheses. Future studies may expand 
upon the idea of spread of degeneration between different WM types in different 
phenotypes of motor neuron disease.  
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ABSTRACT 
Background: MRI Fluid-Attenuated Inversion Recovery (FLAIR) studies reported 
hyperintensity in the corticospinal tract and corpus callosum of patients with Amyotrophic 
Lateral Sclerosis (ALS). Purpose: To evaluate the Lesion segmentation toolbox (LST) for 
the objective quantification of FLAIR lesions in ALS patients. Study type: Retrospective. 
Population: 28 ALS patients (eight females, mean age: 50 range: 24-73, mean ALSFRS-R 
sum score: 36) were compared to 31 age-matched healthy controls (12 females, mean age: 
45, range: 25-67). ALS patients were treated with Riluzole and additional G-CSF 
(Granulocyte-colony stimulating factor) on a named patient basis.  Field strength/ 
sequence: 1.5T, FLAIR, T1-weighted MRI. Assessment: The Lesion Prediction Algorithm 
(LPA) of the LST enabled the extraction of individual binary lesion maps, total lesion 
volume (TLV) and number (TLN). Location and overlap of FLAIR lesions across patients 
were investigated by registration to FLAIR average space and an atlas. ALS-specific 
functional rating scale revised (ALSFRS-R), disease progression and survival since 
diagnosis served as clinical correlates. Statistical tests: Univariate ANOVA, Repeated-
measures ANOVA, T-test, Bravais-Pearson correlation, Chi-square test of independence, 
Kaplan-Meier analysis, Cox-regression analysis. Results: Both ALS patients and healthy 
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controls exhibited FLAIR alterations. TLN significantly depended on age (F(1, 54) = 
24.659; p < .001) and sex (F(1,54) = 5.720, p = .020). ALS patients showed higher TLN 
than healthy controls depending on sex (F(1,54) = 5.720, p = .020). FLAIR lesions were 
small and most pronounced in male ALS patients. FLAIR alterations were predominantly 
detected in the superior and posterior corona radiata, anterior capsula interna and posterior 
thalamic radiation. Patients with pyramidal tract (PT) lesions exhibited significantly 
inferior survival than patients without PT lesions (p = .013). Covariate age exhibited strong 
prognostic value for survival (p = .015). Data conclusion: LST enables the objective 
quantification of FLAIR alterations and is a potential prognostic biomarker for ALS.  
 
INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease involving 
both upper motor neurons (UMN) and lower motor neurons (LMN) as well as non-motor 
areas like the frontotemporal cortex (Al-Chalabi et al., 2016). The diagnostic process for 
this disorder is delayed by the great clinical heterogeneity of ALS phenotypes due to 
variability of onset (limb or bulbar), extent of UMN and LMN involvement and affected 
site (upper or lower limbs, distal or proximal muscles). Facing the psychological impact of 
a life-threatening diagnosis precise ALS diagnosis requires the reliable exclusion of other 
disorders (Tao & Wu, 2017). Electromyography, lumbar puncture, and MRI may provide 
promising biomarkers improving the classification of ALS and the identification of mimic 
disorders (Al-Chalabi et al., 2016; Tao & Wu, 2017). 
MRI findings like cortical thinning of the precentral cortex as well as reduced fractional 
anisotropy of the corticospinal tract (CST) and corpus callosum (CC) are promising 
biomarkers for ALS (Bede, Querin, & Pradat, 2018). CST involvement in ALS may be 
detected by brain MRI as well as spinal cord MRI (Cohen-Adad et al., 2013). Conventional 
Fluid-Attenuated Inversion Recovery (FLAIR) imaging is a T2-weighted MRI sequence 
that eliminates signals derived from free cerebrospinal fluid (Gramsch et al., 2015). FLAIR 
imaging enables the detection of cortical, subcortical and paraventricular lesions and is 
considered a crucial sequence for multiple sclerosis (MS) (Gawne-Cain, et al., 1997; 
Hajnal et al., 1992). In ALS, FLAIR imaging studies could show pathological signal 
increase in the CST (Fabes et al., 2017; Gupta, Nguyen, Chakraborty, & Bourque, 2014; 
Hecht et al., 2001; Jin, Hu, Zhang, Jia, & Dang, 2016; Schweitzer et al., 2015) and the CC 
(Fabes et al., 2017). However, the sensitivity and specificity of FLAIR imaging for ALS 
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are controversial as FLAIR hyperintensity is also detectable in healthy controls (Thorpe et 
al., 1996; Zhang et al., 2003) and was predominantly found in ALS patients with disease 
progress (Protogerou et al., 2011). Only a few studies using FLAIR imaging objectively 
quantified FLAIR alterations in ALS (Fabes et al., 2017; Hecht et al., 2001, 2002; 
Schweitzer et al., 2015). The automated Lesion Segmentation Toolbox (LST) established 
in MS research enables the objective and time-saving quantification of white matter (WM) 
lesions in FLAIR images (Schmidt et al., 2012).  
Thus the aim of this study was to evaluate the potential of LST in the detection of FLAIR 
lesions in ALS patients. We investigated the localization and overlap of FLAIR lesions 
across patients and potential correlations to clinical data.  
 
METHODS 
Participants 
The uni-center project was carried out in accordance with the Declaration of Helsinki 
(World Medical Association) and approved by the local ethics committee (ethics approval: 
15-101-0106). Written informed consent was obtained prior to participation. The sample of 
this study was composed of 28 ALS patients compared to 31 age-matched healthy controls. 
Overall, 25 patients were diagnosed classical limb-onset ALS, whereas another three 
patients exhibited bulbar-onset of disease. All ALS patients received Riluzole standard 
therapy and additional G-CSF (granulocyte-colony stimulating factor, Filgrastim) on a 
named patient basis. Application modes and doses of G-CSF were individually adapted; 
treatment duration was up to 7 years. Safety and monitoring of ALS patients required the 
assessment of ALSFRS-R scores every month and MRI acquisition every three months.  
 
Data acquisition 
Structural FLAIR MRI was performed on two 1.5 Tesla clinical scanners using identical 
settings (Aera, Sonata, Siemens Medical, Erlangen, Germany) with 2D-axial orientation 
(TR = 7530 ms, TE = 110 ms, TI = 2300 ms, FA: 180°, 21 slices, slice thickness: 5mm, 
gap: 0.2, number of averages: 1, matrix: 256 x 196). A FLAIR average template (resolution: 
2mm, n = 853 subjects) (http://brainder.org) served as a reference for the transfer of 
regions of interest (ROI). T1-weighted structural images were assessed in all healthy 
controls and a subset of ALS patients (n = 20) using a magnetization prepared rapid 
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gradient echo sequence (MPRAGE) (TR: 2220 ms, TE: 5.97 ms, FA: 15°, voxel size: 1 x 1 
x 1 mm³, FOV: 256 x 256 mm², 176 sagittal slices covering the whole brain). 
 
Lesion segmentation toolbox  
Individual FLAIR data were analyzed by Lesion Prediction Algorithm (LPA; Schmidt, 
2017) included in the freeware LST version 2.0.15 (www.statistical-modelling.de/lst.html) 
for SPM (SPM12, Matlab Version 2015b). LPA involves a binary classifier based on the 
logistic regression model developed on data from 53 patients with severe MS lesions 
(Schmidt, 2017). The model involves lesion belief maps and considers spatial covariates. 
Based on the model, lesions are segmented by calculation of lesion probabilities for each 
voxel. Raw FLAIR data were preprocessed and lesion probability maps were estimated. 
Values of interest like TLV (total lesion volume in ml) and TLN (number of lesions) were 
extracted by thresholding individual lesion probability maps. Threshold kappa was set to κ 
= 0.5 as this threshold was recommended for LPA SPM12 use (Egger et al., 2016). Binary 
lesion maps thresholded by κ enabled the visualization of individual patients’ FLAIR 
lesions. T1 data are not required for LPA use. However LPA provides the possibility for 
T1 registration in case of low resolution FLAIR images (Schmidt, 2017). A separate 
control analysis involving all healthy controls and a subset of ALS patients (n = 20) 
investigated effects of precedent T1 registration on LPA results. 
 
Locations and Overlap of FLAIR lesions 
Individual FLAIR images of ALS patients were registered to the FLAIR average template 
(http://brainder.org) by linear and nonlinear registration tools (FLIRT, FNIRT) of FSL 
(Freesurfer Version 3.2). Individual binary lesion maps were transferred to an average 
FLAIR template. Localization of FLAIR lesions was performed by the use of a WM atlas 
(Mori et al., 2008). The atlas defines 48 WM areas in average Diffusion weighted imaging 
(DWI) space. Masks of these WM regions were registered from average DWI space to 
average FLAIR space by FLIRT and enabled the description of locations of FLAIR lesions. 
Addition of individual binary lesion maps across ALS patients enabled the investigation of 
size and distribution of FLAIR lesions across individual ALS patients.  
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Quantitative and visual evaluation of FLAIR images 
Results of the LST are compared to visual evaluation in three exemplary patients. Visual 
evaluation was performed by two neuroradiologists with long professional experience 
(S.G.: >30yrs; W.C.: 8yrs). The choice of patients includes one patient evaluated with 
inconspicuous FLAIR images, one patient with unspecific FLAIR lesions and one patient 
with ALS-specific FLAIR lesions in the pyramidal tracts (PT).  
 
Separate control analysis on T1 registration  
A separate control analysis was conducted to investigate effects of preceding T1 
registration on LPA results. The healthy control group (n = 31) and a subset of patients (n 
= 20) were included in this control analysis. Control analysis in patients was restricted to a 
subgroup due to lack of T1 data in eight patients. Threshold κ was set to 0.5 in both groups.  
 
Statistical analysis 
Two univariate ANOVAs (TLV, TLN) took into account factors group (ALS, controls), 
sex, and covariate age and investigated differences in TLV and TLN between all 28 ALS 
patients and all 31 healthy controls. ANOVA effects were analyzed by independent and 
dependent t-tests. Bravais-Pearson correlation analyses examined the relation of TLV and 
TLN to age, ALSFRS-R scores, disease progression rates and elapsed time since diagnosis. 
Chi-square tests of independence were applied to analyze differences in frequencies of 
FLAIR lesions between ALS patients and healthy controls in most affected WM regions. 
Survival since diagnosis was analyzed by the Kaplan-Meier log-rank test. Seven out of 28 
ALS patients were still alive and considered as censored data. In these seven patients, 
survival was calculated as time span between diagnosis and MRI scan. Cox-regression 
analysis was used to investigate effects of potential prognostic factors (age, sex, ALSFRS-
R scores, disease progression rates) on survival. Separate control analysis examined effects 
of precedent T1 registration on LST results. This control analysis was performed using 
repeated-measures ANOVAs including a within-subject factor (with or without preceding 
T1 registration), between subject factors group (ALS, controls) and sex, and the covariate 
age for both TLV and TLN. Significance level was set to p < .05. Multiple comparison 
errors were controlled for by use of Bonferroni correction.  
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RESULTS 
Participants 
28 ALS patients (8 females) were compared to 31 age-matched controls (12 females). The 
characteristics of ALS patients and healthy controls are summarized in Table 2.4.1. ALS 
patients did not significantly differ from healthy controls in age (T(57) = -1.560; p = .124). 
No sex-specific differences in age were detected either between ALS patients and healthy 
controls (females: T(18) = -.826, p = .420; males: T(37) = -1.307, p = .199) or within 
groups (ALS: T(26) = .268, p = .792; controls: T(29) = .076, p = .940).  
 
Table 2.4.1 
Characteristics of ALS patients (n = 28) and age-matched healthy controls (n = 31). ALS 
patients are described by median ALSFRS-R score, median disease progression rate ((48 – 
ALSFRS-R) / months since symptom onset), and elapsed time between diagnosis and MRI 
scan (months).  
 n Mean age 
(yrs) 
Median 
ALSFRS-R 
Median disease 
progression 
rate 
Time since 
diagnosis (months) 
ALS 28 50 .10 
[24-73] 
37.50 
[21-48] 
0.47 
[0-4] 
11 
[1-43] 
Controls 31 45.06 
[25 – 67] 
   
 
 
Total lesion number and volume  
Two univariate ANOVAs (ALS n = 28, healthy controls n = 31) revealed highly significant 
effects of covariate age on both TLV (F(1, 54) = 22.171; p < .001) and TLN (F(1, 54) = 
24.659; p < .001). These findings were supported by highly significant correlations of age 
with TLV (r = .529, p < .001, corrected) and TLN (r = .554, p < .001, corrected). TLN was 
significantly dependent on sex (F(1,54) = 5.720, p = .020) and tended to be higher in male 
compared to female participants (T(57) = 2.261, p = .028, uncorrected). Age was not 
significantly different between male and female participants (T(57) = 0.374, p = .711). 
ALS patients showed a significant increase in TLN compared to healthy controls 
dependent on sex (F(1, 54) = 5.076, p = .028) (Figure 2.4.1a). FLAIR lesions were 
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significantly more frequent in male ALS patients than in female ALS patients (T(26) = 
3.879, p < .001, corrected; males: n = 20, M = 8.55, SD = 5.978, females: n = 8, M = 2.375; 
SD = 2.44) and tended to be more common than in male healthy controls (n = 19) (T(37) = 
-2.020, p = .051). TLN did not significantly differ between female ALS patients and 
female healthy controls (n = 12) (T(18) = 1.237, p = .233) or between female and male 
healthy controls (T(29) = 0.136, p = .893). No significant differences in age were observed 
between female and male ALS patients (T(26) = 0.268, p = .792), between male controls 
and male ALS patients (T(37) = -1.307, p = .199) and between female controls and female 
ALS patients (T(18) = -0.826, p = .420). Most pronounced levels of TLN were observed in 
two patients with bulbar-onset.  
 
 
Figure 2.4.1. Total lesion number and locations of FLAIR lesions detected by LPA. A) 
Total lesion number (TLN) of healthy controls (grey, male: n = 19, female: n = 12) and 
ALS patients (cyan, male: n = 20, female: n = 8). B) % of ALS patients showing FLAIR 
lesions in the most affected WM regions. Ant CR = anterior corona radiata, sup CR = 
superior corona radiata, post CR = posterior corona radiata, post TR = posterior thalamic 
radiation, ant CI = anterior capsula interna. P-values refer to two-sample t-tests. 
 
TLV did not significantly differ between ALS patients and healthy controls (F(1, 54) = 
1.407, p = .241) or between sex (F(1, 54) = 1.639; p = .206). No significant interaction 
effect of sex with group (ALS, controls) was observed for TLV (F(1, 54) = 1.562, p = 
.202). TLN and TLV were strongly intercorrelated (r = .790, p < .001, corrected). 
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Characteristics of FLAIR lesions  
Individual binary lesion maps of ALS patients (n = 28) revealed most frequent FLAIR 
lesions in the callosal genu (n = 27) and body (n = 23), the anterior (n = 24), superior (n = 
20), and posterior (n = 19) corona radiata, posterior thalamic radiation (n = 15) and the 
anterior capsula interna (n = 14) (Figure 2.4.1b). Healthy controls (n = 31) exhibited 
similar frequency of FLAIR alterations in the genu (χ²(1) = 0.253, p = .615, φ = 0.065 ), 
body (χ²(1) = 1.015, p = .314, φ = 0.131) and the anterior corona radiata (χ²(1) = .024, p = 
.877, φ = 0.020). However, FLAIR lesions in the superior (χ²(1) = 6.345, p = 0.012, φ = 
0.328) and posterior corona radiata (χ²(1) = 7.460, p = 0.006, φ = 0.356), posterior 
thalamic radiation (χ²(1) = 6.042, p = 0.014, φ = 0.320), and marginally in the anterior 
capsula interna (χ²(1) = 3.683, p = 0.055, φ = 0.250) were significantly more frequent in 
ALS patients than in healthy controls. FLAIR lesions at the ventricular borders were 
detected in ALS patients as well as in healthy controls. Individual binary lesion maps 
across all ALS patients were accumulated into an overlap lesion map (Figure 2.4.2). 
FLAIR lesions of ALS patients were small (TLV: M = 0.72ml, SD = 0.22) and diffuse. 
65% of voxels with FLAIR alterations showed no overlap between ALS patients.  
 
 
 
Figure 2.4.2. Localization and distribution of FLAIR lesions in ALS patients. Overlap of 
individual binary lesion maps summed up across all ALS patients (n = 28). Ant CR = 
anterior corona radiata, sup CR = superior corona radiata, post CR = posterior corona 
radiata, post TR = posterior thalamic radiation, ant CI = anterior capsula interna.  
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Quantitative and subjective evaluation of FLAIR images 
Results of LST were compared to visual evaluation of FLAIR images by two experienced 
neuroradiologists (Figure 2.4.3). Both neuroradiologists classified the FLAIR images of 
patient 1 (Figure 2.4.3a) as age-related without abnormalities. LST only marked regions at 
the ventricular border. Patient 2 (Figure 2.4.3b) was evaluated with multiple small and 
unspecific WM lesions but weak to no evidence for pathological signal change in PTs. 
Consistent with this visual evaluation, LST detected no lesions in PTs but the presence of 
unspecific WM lesions (white arrow, Figure 2.4.3b). Patient 3 (Figure 2.4.3c) was 
evaluated with symmetrical signal change along the PTs in both LST and visual evaluation 
of the two neuroradiologists. Increased FLAIR signal in the PTs was not evaluated as an 
artifact, as it was persistent across the following brain slices (Figure 2.4.3d). Signal 
changes along the PTs as visualized in patient 3 were marked by LST in 14 out of 28 ALS 
patients.  
 
Clinical correlations  
LST variables did not significantly correlate with disease progression rates (TLV: r = .045, 
p =.820; TLN: r = -.101, p = .608). ALSFRS-R scores at baseline significantly correlated 
with elapsed time between diagnosis and MRI scan (r = -.520, p = .005, corrected). 
However, ALSFRS-R sum scores only weakly correlated with TLV of ALS patients (r = -
.417, p = .027, uncorrected) and showed no significant correlation with survival since 
diagnosis (r = .136, p =.569). A tendency towards association between TLN and survival (r 
= -.445, p = .050, uncorrected) led to the following post-hoc analysis: Patients were 
differentiated into patients with (n = 14) or without (n = 14) PT lesions as detected by the 
LST. Overall estimated mean survival time was 29.08 months since diagnosis (95% CI 
23.31-34.85 months). Kaplan-Meier log-rank test revealed significantly inferior survival 
since diagnosis for patients with PT lesions (95% CI 16.5-27.7 months) compared to those 
without PT lesions (95% CI 26.51-43.04 months) (p = .013) (Figure 2.4.4). Cox-regression 
analysis showed the prognostic value of age (Hazard ratio: 1.067, CI: 1.01-1.12; p = .015) 
for survival. No prognostic value was observed for ALSFRS-R scores (p = .964), disease 
progression rates (p = .154) or sex (p = .245).  
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Figure 2.4.3. Lesion segmentation in three exemplary patients. MRI slices of three limb-
onset patients' (patient 1: 46 yo, male, ALSFRS-R: 39; patient 2: 46 yo, male, ALSFRS-R: 
48, patient 3) 69 yo, male, ALSFRS-R: 21) FLAIR images were evaluated by two 
experienced neuroradiologists and LST (red). A) Patient 1 evaluated with age-related 
FLAIR images. B) Slice of FLAIR images of patient 2 described by unspecific WM 
lesions and weak to no evidence for pathological signal change in the PTs. LST 
successfully detected unspecific WM lesions (white arrows). C) Evaluation of symmetric 
hyperintensity signal in the PTs of patient 3 by both LST and visual evaluation of two 
neuroradiologists. D) Persistent hyperintensity in the PT across the following MRI slices of 
patient 3. Threshold for lesion probability was κ = .50. PT = pyramidal tract. 
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Figure 2.4.4. Prognostic value of pyramidal tract lesions for survival since diagnosis. 
Pyramidal tract (PT) lesions were detected by the LST in 14 out of 28 patients. Kaplan-
Meier analysis revealed significantly inferior survival prognosis for patients with PT 
lesions (dark cyan) compared to those without PT lesions (bright cyan)(p = .013). Seven 
out of 28 patients were still participating in the study and were marked as censored data.   
 
 
Control analysis on preceding T1 registration  
A separate control analysis (ALS n = 20, controls n = 31) investigated bias effects of 
precedent T1 registration on LPA lesion segmentation. Registration to T1 images did not 
significantly affect TLN (F(1, 46) = .008, p = .930). In contrast, TLV was significantly 
increased if LPA was preceded by registration of FLAIR images to T1 images (F(1, 46) = 
7.538, p  = .009). 
 
DISCUSSION 
LST revealed enhanced frequency of FLAIR alterations in male ALS patients. FLAIR 
lesions were small and diffuse and more frequent in ALS patients than in healthy controls 
in the superior and posterior corona radiata, posterior thalamic radiation and anterior 
capsula interna. The presence of PT lesions as detected by the LST was associated with 
inferior survival.  
FLAIR lesions may be interpreted as loss of myelination in fibers (Schmidt et al., 2012). In 
healthy subjects, FLAIR alterations were observed to increase with age (Gawne-Cain et al., 
1997). Consistent with this finding, we detected distinct effects of age on TLN and TLV. 
LST revealed FLAIR hyperintensity in both ALS patients and healthy controls, as reported 
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in other studies (Hecht et al., 2001; Thorpe et al., 1996; Vázquez-Costa et al., 2018; Zhang 
et al., 2003). FLAIR lesions were observed to be dependent on sex and more frequent in 
male ALS patients than in female ALS patients as well as male healthy controls. In 
contrast, healthy controls showed no sex-specific differences in FLAIR alterations, as 
reported by Gawne-Cain et al. (1997). Sex-specific differences in FLAIR lesions were 
reported for MS patients despite balanced age and disease duration (Klistorner et al., 
2016). In ALS research, effects of sex on FLAIR hyperintensity were not detected 
(Vázquez-Costa et al., 2018) or not analyzed (Fabes et al., 2017; Hecht et al., 2001, 2002; 
Ignjatović, Stević, Lavrnić, Daković, & Bačić, 2013; Ngai, Tang, Du, & Stuckey, 2007; 
Schweitzer et al., 2015; Zhang et al., 2003). Sex-specific differences may be due to outliers 
with low TLN in the small sample size of female ALS patients (n = 8). Consistent with this 
consideration, several studies failed to detect FLAIR alterations in all ALS patients of the 
sample (Hecht et al., 2002; Ignjatović et al., 2013; Ishikawa, Nagura, Yokota, & 
Yamaouchi, 1993; Rocha et al., 2004; Thorpe et al., 1996). FLAIR alterations were 
discussed to occur predominantly in patients with progressed stage of ALS (Huynh et al., 
2016; Ignjatović et al., 2013; Thorpe et al., 1996). The two patients with the highest TLN 
had bulbar-onset of disease. This finding is consistent with Vazques-Costa et al. (2018) 
reporting more pronounced FLAIR signal change of the CST in bulbar- compared to limb-
onset patients. Total lesion volumes in ALS patients were comparable to that of healthy 
controls and much lower than in other neurological diseases such as MS (Egger et al., 
2016). These findings are consistent with previous studies reporting the dominant role of 
frequency rather than volumes of FLAIR alterations in ALS (Thorpe et al., 1996; Zhang et 
al., 2003).  
FLAIR lesions in ALS patients were most prominent in the corona radiata and body and 
genu of the CC. These findings are consistent with a study (Fabes et al., 2017) reporting 
most pronounced FLAIR hyperintensity of classical ALS in corona radiata of the CST and 
the body of the CC. Similarly, we observed FLAIR lesions to be more frequent in ALS 
patients than in healthy controls in the superior and posterior corona radiata. FLAIR 
alterations in the CC were shared in both ALS patients and healthy controls. These 
findings may indicate that detected callosal FLAIR lesions may be age-related (Gawne-
Cain et al., 1997) or may result from FLAIR artifacts (Krupa & Bekiesińska-Figatowska, 
2015). Moreover, FLAIR alterations were detected at the ventricular borders. FLAIR 
hyperintensity visualized as thin lines surrounding ventricles is a frequently observed 
phenomenon also in healthy controls (Gawne-Cain et al., 1997) and may be associated 
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with cerebrospinal fluid/vascular pulsation artifacts (Krupa & Bekiesińska-Figatowska, 
2015) or artifacts originating from incomplete signal inversion (Hajnal, Oatridge, Herlihy, 
& Bydder, 2001). However, structural changes at the ventricular borders may as well 
indicate processes in the region of neurogenesis (subventricular zone) (Bergmann, 
Spalding, & Frisén, 2015). LST detected FLAIR alterations at the PT in 14 out of 28 
patients. These lesions often appeared to be symmetric across hemispheres as reported in 
Cheung et al. (1995). The good correspondence of LST results to findings of visual 
evaluation (Hecht et al., 2001; Klistorner et al., 2016; Schweitzer et al., 2015; Thorpe et 
al., 1996) and quantitative evaluation (Fabes et al., 2017; Hecht et al., 2001; Schweitzer et 
al., 2015) argue for the potential of LST use. The interpretation of numerical TLN and 
TLV should be careful, as LST may be biased by hyperintensity derived from incomplete 
signal inversion along the ventricular walls resulting in CSF-ventricular-border-artifacts. 
Still, LST was capable in the fast and objective detection of intracerebral lesions. 
Correlations of both ALSFRS-R and disease progression rates with LST variables were 
rather weak or not detectable. Lack of correlation between FLAIR intensity and clinical 
data was frequently reported in both visual evaluation studies (Gupta et al., 2014; Jin et al., 
2016; Peretti-Viton et al., 1999) and quantitative studies (Hecht et al., 2001, 2002).  
Kaplan-Meier analysis detected inferior survival for patients with PT lesions compared to 
patients without PT lesions. Thus, LST may not only help to monitor intracerebral lesions 
but may also contribute to prognosis and diagnosis of different ALS phenotypes. Cox-
regression analysis revealed significant prognostic value of age for survival. This is 
consistent with Pupillo, Messina, Logroscino & Beghi (2014) showing age as one of the 
most relevant prognostic factors of ALS survival. Baseline ALSFRS-R score significantly 
correlated to elapsed time between diagnosis and MRI scan but had no predictive value for 
the survival of patients. Prognostic values of sex, ALSFRS-R scores, and disease 
progression rates on survival were less consistently reported than that of age (Chiò et al., 
2009). 
Several methodological limitations may be considered. First, sample size was limited to n 
= 28 patients. The subset of female patients did not show severe FLAIR lesions potentially 
affecting group statistics. Still, sample size was adequate to detect higher frequency of 
FLAIR lesions in male patients at group level. Second, the sample included both limb-
onset and bulbar onset patients. Lack of balanced sample sizes (limb-onset: n = 25, bulbar-
onset: n = 3) allowed for no statistical test for ALS onset. A separate control analysis 
revealed that TLV was biased by precedent T1 registration. TLN was stable in T1 
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registration. Thus, precedent registration of lower resolution FLAIR data to higher 
resolution T1 images may bias size of detected FLAIR lesions.  
 
Conclusion 
In conclusion, LST is an accessible and time-saving tool for objective quantification of 
FLAIR alterations in ALS. The predictive value of FLAIR alterations for survival 
prognosis underlines the relevance of monitoring FLAIR images in ALS patients and its 
potential for the classification of ALS phenotypes. Future studies may explore FLAIR 
alterations detected by LST in different ALS subtypes and ALS mimic disorders to 
underline ALS-specificity of these FLAIR lesions.  
 
Contributions of authors:  
Wirth: conception and design of the study, acquisition, analysis, interpretation of MRI 
data, and composition of the manuscript. 
Johannesen, Bruun, Bogdahn: contribution to the conception of the study; acquisition, 
analysis, and interpretation of clinical data, and revision of the manuscript.  
Khomenko, Baldaranov: data acquisition and revision of the manuscript.  
Johannesen, Khomenko, Baldaranov, Bogdahn: care for ALS patients in outpatient clinic, 
treatment concept.  
Schuierer, Wendl: MRI data acquisition and visual evaluation of MRI data 
Greenlee: contribution to the conception of the study, supervision of MRI data analysis 
and data interpretation, and revision of the manuscript.  
 
Acknowledgements: 
This work was supported by the German Federal Ministry of Education and Research 
(BMBF, Project GO-Bio). 
 
Conflict of Interest Statement:  
The authors declare no commercial or financial conflicts of interest. 
 
 
 
 
77 
CHAPTER 3: CONCLUDING REMARKS 
CHAPTER 3: CONCLUDING REMARKS   
 
SUMMARY OF FINDINGS OF THIS THESIS  
 
The aim of the thesis is to evaluate the potential of candidate MRI biomarkers for ALS. 
The subprojects focus on structure of both WM and GM of the brain using T1-weighted 
imaging, DWI, and FLAIR MRI. The analysis of candidate MRI biomarkers includes 
conventional cross-sectional group analysis but also focuses on the individual patient 
perspective and specifically longitudinal monitoring. Combinatory biomarker use is 
emphasized by the association of MRI biomarkers with clinical and neurophysiological 
biomarkers.  
Study 1 reveals that cortical thinning of the precentral cortex is a prominent but not 
omnipresent feature of ALS patients. Precentral cortical thinning is linked to age and 
disease progression. Combinatory biomarker use of MRI, clinical, and neurophysiological 
biomarkers underlines the potential gain of information. Moreover, study 1 reveals 
substantial differences in the temporal dynamics of specific biomarkers challenging the 
detection of correlations between them. Precentral cortical thinning cannot be used as a 
diagnostic criterion for ALS per se. However, cortical thinning may be used as a 
monitoring biomarker capable of the differentiation of ALS patients in different disease 
and progression types. Moreover, the combinatory biomarker use with neurophysiological 
MUNIX may help to describe levels of involvement of UMN and LMN in complex 
classical ALS and therefore help to establish definite ALS diagnosis.  
Study 2 shows that FA alterations are specific to region and type of WM in ALS patients. 
Reduced levels of FA are primarily detected in the CST and non-motor WM areas. FA 
alterations are predominant in the brainstem and spread to other types of WM. Spread of 
WM alterations is observed to occur in both dying-forward and dying-back manner. Still, 
patients with either dying-forward or dying-back patterns of disease spreading do not 
significantly differ in clinical scores, disease progression, or survival. Moreover, dying-
forward or dying-back spread is not associated with gender or onset of disease in classical 
ALS. The findings indicate that both patterns of disease spread may exist in classical ALS. 
Therefore, FA may be used as a diagnostic biomarker potentially contributing to the 
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understanding and the differentiation of ALS disease propagation mechanisms and 
individual phenotype.  
Study 3 underlines the great potential of the LST for the fast and objective evaluation of 
FLAIR images in ALS. LST is highly sensitive to intracerebral lesions and corresponds 
well to the visual evaluation of FLAIR images. LST may be considered a promising and 
easily accessible tool enabling one step beyond visual evaluation studies. FLAIR imaging 
does not appear to provide a strict diagnostic criterion for ALS. However, LST may help to 
standardize quantification of FLAIR hyperintensity signal as a highly relevant exclusive 
biomarker of ALS mimics. Moreover, FLAIR lesions of the PTs are associated with 
inferior survival. These findings reveal the hidden potential of conventional FLAIR 
imaging as a source for prognostic biomarkers for ALS.  
In summary, structural MRI may contribute to the diagnosis (FA), the monitoring of 
disease progression (cortical thickness, FA), and the prognosis (FLAIR hyperintensity) of 
ALS. All structural MRI biomarkers investigated in this thesis show their potential to add 
to the understanding of pathogenesis of ALS.   
 
THE CHANGING SCENE OF MRI BIOMARKERS  
 
The last decade of ALS research has changed the perspective on ALS and its neuroimaging 
biomarkers. The following three emerging aspects of MRI biomarker research have had an 
essential influence on the aims and the study designs of this thesis: understanding 
neurodegenerative disease, multimodal MRI use, and individual perspective.  
First, biomarkers are not only needed to enlarge ALS-specific diagnostic criteria, but also 
more generally to deepen our understanding of neurodegenerative diseases. Biomarkers 
enable the differentiation of ALS from so-called mimic disorders (Agosta et al., 2010). 
However, biomarkers may as well help to find commonalities with other 
neurodegenerative diseases (Eisen et al., 2014). Similar to other neurodegenerative 
diseases, ALS is characterized by a long presymptomatic period (Eisen et al., 2014), 
frequent genetic background (Calvo et al., 2014) and fast disease propagation (Ludolph & 
Brettschneider, 2015). Moreover, ALS is considered to potentially overlap with the 
behavioral variant of frontotemporal dementia (Zago, Poletti, Morelli, Doretti, & Silani, 
2011). The accumulation and spread of protein aggregations in the brain are considered 
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communalities of ALS with Parkinson’s disease and Alzheimer’s disease (Ludolph & 
Brettschneider, 2015). These findings have lead to the controversial discussion of ALS 
being a spreading prion-like disease (Ludolph & Brettschneider, 2015). Spread of WM 
degeneration has been investigated by stage-wise degeneration of specific WM tracts 
(Kassubek et al., 2014). Study 2 makes a further step by investigating dying-forward and 
dying-back hypotheses as reflected in the spread of WM type-specific FA alterations.    
Second, it is not essential to find the one and only MRI biomarker for ALS but rather an 
MRI footprint of ALS by multimodal MRI use (Ferraro et al., 2017). Routine anatomical 
imaging like T2-weighted imaging and FLAIR are useful for the exclusion of MRI mimic 
disorders (Agosta et al., 2010). However, advanced techniques like DWI and voxel-based 
morphometry appear to be more promising biomarkers for disease progression and ALS 
diagnosis (Wijesekera & Leigh, 2009). Both GM and WM pathology have been detected 
(Zhang et al., 2014). However, MRI studies have revealed more consistent WM than GM 
involvement in ALS (e.g. Cardenas-Blanco et al., 2016, Christidi et al., 2018). Bede & 
Hardiman (2014) discuss that WM alterations may be detectable earlier in disease than GM 
changes suggesting that WM alterations may be more helpful as monitoring biomarkers.  
Consistent with this theory, the current thesis detects common FA alterations, but 
precentral cortical thinning only in about half of the patient cohort. Consistent with Ferraro 
et al. (2017), multimodal MRI biomarker use of cortical thickness, FA, and FLAIR 
hyperintensity in the same patient cohort results in a substantial gain of information. The 
thesis fulfils these criteria, as it has assessed multimodal MRI techniques in the same 
patient cohort. 
Third, ALS is no longer considered a single disease but rather as a spectrum of various 
syndromes of MND (Turner et al., 2013; Wijesekera & Leigh, 2009). ALS includes 
complex variations of phenotypes, onsets, and progression types (Eisen et al., 2014). The 
latest version of El Escorial criteria enables the coarse categorization into possible, 
probable and definite ALS (Costa et al., 2012). However, El Escorial criteria cannot cope 
with the heterogeneity of ALS phenotypes, which may have a substantial impact on the 
prospects of success of clinical trials (Al-Chalabi et al., 2016). Biomarkers like 
neuroimaging may improve diagnosis and classification of ALS (Verstraete & Foerster, 
2015). For this purpose, future studies need to include detailed descriptions of ALS 
phenotypes in their samples (Al-Chalabi et al., 2016). Most importantly, MRI studies in 
ALS may go beyond group averages and focus on the individual patient (Turner et al., 
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2013). Accordingly, a special focus of this thesis is set on the detailed description of the 
individual patients of the sample. 
MRI research of the last decades has been further developed and has contributed to the 
current understanding of ALS (Al-Chalabi et al., 2016; Chiò et al., 2014). Still, MRI 
biomarker research is challenged by a number of technical and methodological caveats. 
These challenges have also influenced the methodological approaches of this thesis.  
 
CHALLENGES OF MRI BIOMARKER RESEARCH  
 
MRI biomarker research for ALS includes various MRI approaches, heterogeneous cohorts 
of ALS phenotypes, and various clinical correlates. These manifold approaches may offer 
broad perspectives, but may as well challenge comparability of findings (Chiò et al., 2014). 
Variability of MRI approaches. MRI studies may involve conventional MRI like FLAIR 
(e.g. Ishikawa et al., 1993), T1-weighted imaging (e.g. Großkreutz et al., 2006) or 
advanced imaging techniques like DWI, fMRI, and MRS (Agosta et al., 2010). 
Morphometric studies may investigate cortical thickness (e.g. Walhout et al., 2015), 
volumes (e.g. Bede et al., 2013) or areas (e.g. Verstraete, Veldink, Mandl, van den Berg, & 
van den Heuvel, 2011) of the precentral cortex. In turn, cortical thickness may be assessed 
by either vertex-based approaches (e.g. Walhout et al., 2015) or ROI-based approaches 
(e.g. Bede et al., 2013). ROI-based approaches are usually based on atlas definitions (e.g. 
Desikan et al., 2006). DWI has given rise to the investigation of diffusion properties of the 
CST. FA and MD are the most commonly investigated diffusion properties in ALS 
research (Chiò et al., 2014). However, several DWI studies have also included the analysis 
of radial diffusivity and axial diffusivity (e.g. Metwalli et al., 2010). DWI variables may be 
approached by either voxel-based (Chapman et al., 2014) or ROI-based methods (Keil et 
al., 2012). The ROI of CST may be defined by either an atlas (e.g. Kwan et al., 2012) or 
DTI tractography (Kassubek et al., 2014). The DTI model enables approaches for 
deterministic or probabilistic tractography (Descoteaux et al., 2009). Both deterministic 
(e.g. Kassubek et al., 2014) and probabilistic (Steinbach et al., 2015) tractography have 
revealed alterations in the CST of ALS patients. Probabilistic tractography is considered to 
be more sensitive and specific than the deterministic approach (Thomas et al., 2014). 
However, no study has yet investigated differences in findings between deterministic and 
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probabilistic tractography in the same ALS sample. The choice of tractography thresholds 
and seed procedures are among the crucial factors for comparability of tractography 
methods (Zhan et al., 2015). The CST may be defined by tracking from seed regions in 
either the pons (e.g. Steinbach et al., 2015) or the capsula interna (e.g. Ciccarelli et al., 
2006), respectively. In FLAIR imaging, studies on visual evaluation including rating scales 
and independent raters broadly dominate the field (e.g. Hecht et al., 2001). However, new 
methods of objective quantification of FLAIR signal open up new vistas for FLAIR 
imaging (Fabes et al., 2017). In summary, MRI research in ALS provides a broad range of 
different methods and restrictions but also with various perspectives and possibilities. 
Detailed description of MRI approaches may ease their comparison and enable their 
combination in ALS cohort studies (Ferraro et al., 2017).  
Variability of patient cohorts. Comparing findings of different MRI studies is challenged 
by variable patient cohorts with different clinical characteristics and demography (Chiò et 
al., 2014). MRI biomarker studies may be restricted to specific ALS phenotypes (e.g. 
primary lateral sclerosis; Kuipers-Upmeijer, Jager, Hew, Snoek, & van Weerden, 2001) or 
may compare between different ALS phenotypes (e.g. Mezzapesa et al., 2013). Patient 
subgroups may differ in genetic background (e.g. Westeneng et al., 2016), onset of disease 
(e.g. Cardenas-Blanco et al., 2014), extent of UMN and LMN involvement (Van der Graaff 
et al., 2011), or in overlap with frontotemporal dementia (Omer et al., 2017). Moreover, 
ALS subtypes may be compared to ALS mimic disorders (e.g. Walhout et al., 2015). 
Patient cohorts of different MRI studies may vary in duration of disease (1/2 year – 15 
years, Chiò et al., 2014), mean age (e.g. 52 yrs: Thivard et al., 2007; 64 yrs: Cosottini et 
al., 2005), or mean baseline ALSFRS-R score (e.g. 40 score points: Verstraete et al., 2011; 
23 score points: Meadowcraft et al., 2015). Moreover, ALS patient samples may differ in 
ethnic origin (e.g. China: Tang et al., 2015; Germany: Grosskreutz et al., 2006). Ethnic 
background may be crucial, as population-based registers reveal ethnic differences in 
prevalence and incidence of ALS (Hardiman et al., 2017). Variability of patient samples 
challenges the comparison between studies and their generalization (Chiò et al., 2014). 
However, failures of several clinical trials indicate that response to treatment may depend 
on ALS phenotypes (Mitsumoto et al., 2014). Therefore, the focus on specific ALS 
phenotypes may be trend-setting for improving ALS classification (Al-Chalabi et al., 2016) 
and for understanding the manifold pathogenic processes of ALS (Grad, Rouleau, Ravits, 
& Cashman, 2017). 
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Choice of clinical correlates. Disease-related changes in structure and function are 
considered to affect clinical outcome (Chiò et al., 2014). Therefore, MRI biomarker 
research needs to involve clinical correlates. ALSFRS-R is the most commonly used 
clinical correlate in MRI studies (e.g. Rutkove, 2015). ALSFRS-R is prominent in clinical 
routine and is considered a reliable clinical score for the severity of disease (Rosenfeld & 
Strong, 2015). However, correlations of ALSFRS-R with MRI candidate biomarkers like 
precentral cortical thinning (e.g. De Albuquerque et al., 2016), reduced FA of the CST 
(e.g. Borsodi et al., 2017) or FLAIR hyperintensity (e.g. Hecht et al., 2002) are rather weak 
or not at all detected. These results may be explained by ALSFRS-R being a rather general 
severity scale influenced by both UMN and LMN signs (Cardenas-Blanco et al., 2016). In 
addition to ALSFRS-R, prominent clinical correlates of MRI studies include disease 
duration, disease progression rate, survival, or burden scales (Grolez et al., 2016). The 
increasing interest in ALS-FTD overlap and cognitive deficits in ALS has led to the 
recommendation of neuropsychological assessment in clinical trials (Dorst et al., 2018) and 
MRI studies (Christidi et al., 2018). The inclusion of a broad range of valid clinical 
correlates may contribute to a detailed description and differentiation of ALS patient 
cohorts (Grolez et al., 2016).  
The subprojects of this thesis have been challenged by a variety of methodological 
challenges which have also affected the majority of MRI studies in ALS research: small 
sample sizes, restricted data quality, adequacy of control samples, lack of standardization, 
and statistical shortcomings (Chiò et al., 2014).  
Small sample sizes. Only very few published studies exhibit sample sizes greater than 30 
subjects per group (Grolez et al., 2016). Small sample sizes may be due to flow occurrence 
of ALS cases (Nagel, Unal, Rosenbohm, Ludolph, & Rothenbacher, 2013) or high MRI 
drop-out rates (Grolez et al., 2016), among other factors. MRI is a time-consuming 
technique associated with patient discomfort (Benatar et al., 2016). ALS patients often 
drop out of studies due to respiratory problems, increasing disability, or even death (Grolez 
et al., 2016). Small sample sizes do not only lead to variable results, but also challenge 
subgroup analysis. Facing the problems of sample sizes in unicenter studies, the 
Neuroimaging Society in Amyotrophic Lateral Sclerosis (NiSALS) has initiated the 
cooperation of MRI research units for an international and multicenter investigation of 
MRI biomarkers (Filippi et al., 2015).  
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Lack of standardization. Comparability and reproducibility of MRI studies in ALS 
research are often challenged by the variability of imaging sequences and analytical 
methods (Verstraete & Foerster, 2015). Additionally, several studies lack a detailed 
description of MRI equipment, sequence parameters, and data processing (Chiò et al., 
2014). As MRI scanners and sequences are highly heterogeneous between centers, 
multicenter MRI research as proposed by Filippi et al. (2015) include general guidelines 
for the acquisition and analysis of good quality and comparable MRI data in ALS.  
Data quality. One major issue in clinical MRI research is pragmatism (Benatar et al., 
2016). MRI assessment requires technical equipment, expertise, and high costs. Most MRI 
studies on ALS before 2010 used MRI scanners with 1.5T field strength. MRI scanners 
with 3T or even 7T are not available in every hospital (Bede & Hardiman, 2014). 
Reduction of MRI acquisition time may decrease patient discomfort and lead to lower 
drop-out rates (Hollingsworth, 2015). However, reduced scan acquisition time may lead to 
MRI images with lower resolution or reduced number of orientations in DWI (e.g. 5mm 
resolution and six DWI orientations: Abe et al., 2004). This data quality may not be 
sufficient for advanced imaging data analysis like probabilistic tractography (Behrens, 
Berg, Jbabdi, Rushworth, & Woolrich, 2007) or voxel-based morphometry (Ashburner & 
Friston, 2000). Another problem in clinical MRI research is the change of scanner types or 
sequences within a study. Therefore, technical equipment and sequence parameters should 
be described in detail (Chiò et al., 2014).  
Inappropriate control samples. Control samples are often small (Grolez et al., 2016) and 
not adequate as controls for ALS samples (Chiò et al., 2014). Specifically, control samples 
frequently suffer from an insufficient match of age and gender, and often miss detailed 
description (e.g. cognitive status). Inclusion of age and gender correction in statistical 
models may help to overcome this caveat (Bede & Hardiman, 2014). Moreover, the 
inclusion of disease control samples like e.g. ALS mimics may be trend-setting to 
investigate specificity of MRI biomarkers for ALS (e.g. Ferraro et al., 2017).  
Statistical shortcomings. Reliability and reproducibility are enormously challenged by 
statistical shortcomings in neuroimaging (Zugman, Sato, & Jackowski, 2016). MRI studies 
facing low sample sizes often struggle with limited statistical power (Nagel et al., 2013) 
resulting in no significant differences between ALS patients and controls and weak 
correlations with clinical variables. This leads to the following dilemma: On the one hand, 
liberal statistical testing (e.g. lack of multiple comparison correction) may lead to false 
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positive results (Bede & Hardiman, 2014). On the other hand, conservative statistical 
testing may increase risk of neglecting positive results or potential tendencies (Bennett, 
Wolford, & Miller, 2009). The key to solve this problem may be the plain description of 
positive as well as negative results and a critical interpretation of both.  
The three subprojects of this thesis have handled these challenges by adapting their 
methods, aims, and study designs. The following section discusses the benefits and 
drawbacks of these methods.  
 
DISCUSSION OF METHODS AND DESIGNS OF THIS THESIS  
 
Restriction to retrospective data. The data analysis of the treatment program is limited to 
the time window of 2010 – 2017. No additional patients have been included into MRI data 
acquisition after this period. These conditions exacerbated the collection of an adequate 
ALS sample of more than five patients for prospective studies. Therefore, the thesis 
focuses on retrospective patient data acquired since 2010. Retrospective data enables the 
analysis of longitudinal time courses of MRI biomarkers and fulfils the aim of ALS sample 
sizes of at least 20 patients.  
Choice of MRI approaches due to restricted data quality. Retrospective data dates back 
to 2010, when MRI technology was ruled by different standards than used in recent MRI 
studies (Bede & Hardiman, 2014). All data sets were acquired with 1.5T MRI scanners 
with low resolution of DWI and FLAIR data. A slice thickness of 5mm in DWI and 
FLAIR data hinderes the conduction of voxel-based approaches. Thus, all projects of this 
thesis use ROI-approaches base on atlas definitions (Mori et al., 2008; Yeo et al., 2011). 
Moreover, ROIs are rather large (Study 1: ventral and dorsal precentral/postcentral cortex) 
or summed up to larger ROIs (Study 2: WM types). The low resolution of MRI data is 
carefully discussed in the methodological limitations of the subprojects. Another caveat of 
data quality is the change of DWI sequence during the study period. Modification of DWI 
sequence from six to 20 orientations challenges both cross-sectional and longitudinal data 
analysis. A control analysis of 22 healthy controls scanned with both DWI sequences on 
the same acquisition day has revealed evident bias effects of DWI sequence change on FA 
values (Supplementary figure 1A, Appendix 3). Ignoring these biases may have led to 
erroneous results and interpretations. DWI sequence change within the time course of a 
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single patient would have induced the analysis and fatal interpretation of FA increase over 
time (Supplementary figure 1B, Appendix 3). Calculation of multiplication factors for 
every WM region overcomes these bias effects and enables the conduction of cross-
sectional and longitudinal analysis without excessive drop-out of data sets. Even after 
modification of DWI sequence, DWI data quality restricts DWI data analysis. Probabilistic 
tractography is considered to require at least 30 orientations of DWI data (Behrens et al., 
2007). Deterministic tractography would have been possible with DWI20. Still, slice 
thickness of 5mm of DWI data is not adequate for tractographic analysis. Therefore, DWI 
data analysis is restricted to basic methods like extraction of mean FA for specific ROIs.   
Variability of patient cohorts. The ALS patient cohort of this thesis includes 28 limb-
onset and three bulbar-onset patients. Both bulbar-onset and limb-onset ALS patients are 
characterized by UMN and LMN signs. Unbalanced sample sizes for bulbar and limb-
onset ALS patients do not allow for subgroup analysis. However, ALS patients are 
differentiated into either arm or leg onset. The ALS sample of this thesis differs from other 
MRI studies with respect to the younger age of our patients. Usually, ALS patient cohorts 
are aged 60 years in average (64 yrs in Cosottini et al., 2005). Here, our ALS sample is 
aged 50 years on average and includes several young-onset patients. Young-onset ALS is 
associated with better prognosis (Chiò et al., 2011) and slow disease progression (Orban, 
Devon, Hayden, & Leavitt, 2007). Consistent with these findings, the two youngest ALS 
patients exhibit slow disease progression and longitudinal survival. Facing high drop-out 
rates in MRI studies, slow progressive patients enable the longitudinal monitoring of MRI 
biomarkers (Menke et al., 2017). On the one hand, these patients may represent only a 
small subtype of ALS and challenge generalizability of findings. On the other hand, ALS 
research of the past 10 years has underlined that the focus on homogenous subtypes of 
ALS may be the key towards understanding and treating ALS (Al-Chalabi et al., 2106; 
Mitsumoto et al., 2014). For this purpose, the subprojects provide detailed clinical data of 
ALS cohorts and emphasize the perspective on the individual patient as recommended by 
Chiò et al. (2014) and Simon et al. (2014).  
Choice of clinical correlates. Detailed description of ALS cohorts requires the acquisition 
of numerous clinical correlates. Most MRI studies in ALS research involve clinical 
correlates like ALSFRS-R sum scores and subscores, disease duration and disease 
progression rates (Grolez et al., 2016). All three subprojects of the thesis fulfil the 
inclusion of these basic clinical correlates. Still, the thesis may have benefited from 
acquisition of further clinical correlates like UMN burden scale (Mezzapesa et al., 2013), 
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UMN rapidity index (Iwata et al., 2011), spasticity scale (Ellis et al., 1999) or muscular 
strength (Poujois et al., 2013). One major caveat of this thesis is the lack of 
neuropsychological data. The relevance of neuropsychological assessment for clinical trials 
(Mitsumoto et al., 2014), and multidisciplinary care of ALS patients (Hogden, Foley, 
Henderson, James, & Aoun, 2017) has gradually increased over the last ten years. Still, 
neuropsychological evaluation is underrepresented in MRI ALS research (Christidi et al., 
2018). Survival is considered a standard outcome variable in ALS clinical trials although 
survival may not be an adequate correlate for disease progression (Rutkove, 2015). Still, 
survival is considered an important clinical correlate for the evaluation of MRI as a 
prognostic biomarker. Consistent with this notion, study 3 detects prognostic value of 
FLAIR imaging for ALS survival.  
Small sample sizes. The thesis has been challenged by a small sample size of ALS 
patients. In total, the treatment program involves 36 ALS patients. Some of these patients 
have dropped out of the studies due to exclusion from MRI acquisition or lack of specific 
MRI sequences. While DWI and FLAIR data have consistently been acquired since 2010, 
T1-weighted imaging has been included into the standard MRI protocol as recently as 
2013. Therefore, study 1 may have included the same patients as in study 2 or 3 at a later 
stage of disease. All projects account for these possible bias effects by taking into account 
the current severity of disease (ALSFRS-R), disease progression rates, and time elapse 
since diagnosis at the time point of so-called baseline MRI scan. A greater number of ALS 
patients would have enabled subgroup analysis (e.g. limb-onset, bulbar-onset). Still, ALS 
is a rare disease and sample size is comparable to those of other unicenter MRI studies 
(e.g. Cosottini et al., 2013; Grosskreutz et al., 2006; Roccatagliata et al., 2009; Verstraete 
et al., 2010). 
Inappropriate control samples. Recruitment and MRI acquisition of age-related healthy 
controls are main aspects of the thesis. As most of these healthy controls are clinical staff 
or related to the research unit, the control sample may have been influenced by selection 
bias. Still, these participants serve as an age-matched control group for ALS patients and 
enable methodological control analyses (e.g. DWI sequence change). The thesis may have 
benefited from a control sample without G-CSF treatment or control groups with other 
neurological diseases. An ALS control sample without G-CSF treatment would have 
enabled the investigation of potential effects of G-CSF. However, the acquisition of this 
control sample has not been part of the treatment program. Additional control samples with 
other neurodegenerative diseases would have underlined the ALS-specificity of results. 
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However, the ethics-committee approval has been restricted to MRI acquisition in ALS 
patients and healthy controls.   
Lack of standardization. The three studies included in this thesis use different MRI 
approaches. Study 1 investigates T1-weighted imaging. Study 2 focuses on DWI, whereas 
study 3 examines FLAIR imaging. Still, different MRI sequences of this thesis enable the 
differentiated evaluation of MRI as a biomarker in the same preselected cohort. MRI 
variables of interest (cortical thickness, FA) are transformed to z-transformed deviations of 
age-related healthy controls. This standardization procedure facilitates the comparison of 
findings of this thesis. Bias effects of change of DWI sequence on FA are controlled for 
and corrected by multiplication factors and z-standardization. All projects of this thesis 
have been conducted using the same software programs (Freesurfer 5.3, SPM, Matlab).  
Statistical shortcomings. Increased sample size of ALS patients may have enhanced 
statistical power and may have rendered a broader range of statistical analyses possible 
(e.g. cluster analysis). Thus, the subprojects of this thesis have been restricted to rather 
basic statistical analyses like ANOVA, t-test, chi-square tests for independence, correlation 
analyses, Kaplan-Meier analysis and Cox-regression. While projects 1 and 3 include 
multiple comparison correction, region-specific t-tests of project 2 does not. The choice of 
WM regions for WM type ROIs is based on results of uncorrected t-tests. This procedure 
has to be used as multiple comparison correction may have eliminated the full choice of 
WM regions for commissural WM and may have led to no ROI definition of WM type CF 
at all.  
In summary, the thesis may have benefited from better MRI data quality, increased ALS 
sample size, and additional correlates and control samples. Still, handling common 
challenges of MRI ALS research marks this thesis as a worthwhile approach towards the 
evaluation of potential MRI biomarkers in clinical routine ALS data.   
 
CONCLUSION AND FUTURE OUTLOOK  
 
In conclusion, this thesis may increase awareness for both the potential and the challenges 
of MRI biomarker research in a rare, complex and heterogeneous disease like ALS. GM 
and WM structure of ALS patients are investigated using different MRI sequences and 
approaches. Candidates of MRI biomarkers are associated with neurophysiological and 
 
 
 
88 
CHAPTER 3: CONCLUDING REMARKS 
clinical biomarkers and monitored in the individual patient and in longitudinal courses of 
disease.  
The findings of this thesis underline that MRI biomarkers may have great potential in 
diagnosis (DWI FA), prognosis (FLAIR), and longitudinal monitoring (cortical thickness) 
of ALS disease. Moreover, they may reveal potential propagation mechanisms and 
contribute to etiopathological understanding of ALS. Combination of different MRI 
modalities in the same patient may be rather more promising than searching for the unique 
MRI biomarker. Moreover, MRI biomarkers should be associated with other types of 
biomarkers (clinical, neurophysiological, molecular etc.). Multimodal biomarker use, 
detailed description of ALS phenotypes, and an individual perspective may contribute to 
the characterization of biomarker fingerprints of ALS subtypes.  
The thesis has been conducted on behalf of a treatment program on a named patient basis 
for G-CSF. The results of this thesis may contribute to the evaluation of MRI approaches 
for prospective MRI biomarker studies in the treatment program. Moreover, the thesis may 
help to plan the set-up of MRI in a potential future clinical trial or broader application of 
G-CSF.  
Future MRI research on ALS may try to bridge two challenges of ALS: ALS MRI research 
may aim at an improvement of data quality, enhanced sample sizes, adequate control 
samples, detailed description of ALS phenotypes, and a broad range of clinical correlates. 
Still, useful MRI biomarkers may be characterized by validity, applicability, feasibility, 
and above all: tolerability for the patients. By solving this dilemma, MRI biomarkers may 
help to take a further step towards the understanding and the cure of ALS disease. In 
addition, MRI biomarkers may help to bridge the huge time gap between an initially 
effective systemic medical treatment and the by far delayed functional benefits for the 
patient, when healthier neurons will restructure spinal cord and spinal nerves including the 
connected musculature.   
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Supplementary figure 1. Correction of DWI sequence derived biases on fractional 
anisotropy. A) Control analysis on sequence derived biases on FA in 22 healthy controls. 
Excerpt of three out of 48 atlas-based WM regions (Mori et al. 2008) showing distinct 
deviations of FA of former DWI sequence (DWI6) from that of modified DWI sequence 
(DWI20). Calculation of multiplication factors enables the rise of FA levels of DWI6 to 
the level of DWI20. B) Effect of sequence derived biases on the evaluation of the 
longitudinal course of FA in the callosal body of an exemplary patient with 12 MRI scans. 
DWI sequence has been modified after six MRI scans. Without FA correction, the course 
may have been evaluated as an increase of FA. Correction of sequence derived biases on 
FA has helped to elucidate these erroneous interpretations.  
 
